ЖЕНСКИЕ ГИГИЕНИЧЕСКИЕ АБСОРБИРУЮЩИЕ ИЗДЕЛИЯ, СОДЕРЖАЩИЕ АБСОРБИРУЮЩИЕ ВОДУ КОМПОЗИЦИОННЫЕ МАТЕРИАЛЫ

FIELD: personal use articles. SUBSTANCE: invention relates to women hygienic absorbent article comprising the water absorbing composite materials obtained by foaming an aqueous mixture containing at least one monoethylene unsaturated monomer bearing acid groups, at least one crosslinking agent, at least one initiator, and at least one surfactant of contacting with the resulting foamed material with at least one web of synthetic fibres, and polymerisation, to the composite materials themselves, as well as their use for absorption of aqueous liquids. EFFECT: improved properties of women hygienic absorbent articles containing superabsorbent foamed materials, in particular by providing foamed materials that have good absorbent, retaining and conducting properties of aqueous liquids and are stable, particularly when wet, handled effectively, processed effectively and simple in the manufacture, providing of women hygienic absorbent articles containing superabsorbent foamed materials which swell only in one dimension and that do not shrink in drying. 14 cl, 1 tbl РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (51) МПК A61F 13/15 (11) (13) 2 568 100 C2 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ОПИСАНИЕ (21)(22) Заявка: ИЗОБРЕТЕНИЯ К ПАТЕНТУ 2013149943/12, 16.05.2012 (24) Дата начала отсчета срока действия патента: 16.05.2012 Приоритет(ы): (30) Конвенционный приоритет: (43) Дата публикации заявки: 27.06.2015 Бюл. № 18 (45) Опубликовано: 10.11.2015 Бюл. № 31 (73) Патентообладатель(и): ДЗЕ ПРОКТЕР ЭНД ГЭМБЛ КОМПАНИ (US) (85) Дата начала рассмотрения заявки PCT на национальной фазе: 18.12.2013 2 5 6 8 1 0 0 (56) Список документов, цитированных в отчете о поиске: US 2005228350 A1, 13.10.2005WO 2006106108 A1, 12.10.2006WO 02094328 A2, 28.11.2002 WO 9731971 A1, 04.09.1997 US 4324246 A, 13.04.1982 R U 18.05.2011 US 61/487,403 (72) Автор(ы): ДИ СИНТИО Акилле (IT), ЗИЕМЕР Антье (DE), КАЛУЗА Хорст Юрген (DE), БАУЕР Эрнст Юрген (DE), БРУНС Стефан (DK), ДАНИИЛ Томас (DE), ШМИТТ ...

ПРЕДОТВРАЩЕНИЕ, РАЗРУШЕНИЕ И ОБРАБОТКА БИОПЛЕНКИ ЛИЗИНОМ БАКТЕРИОФАГА

Группа изобретений относится к способам для предотвращения образования, а также разрушения или эрадикации биопленок грам-положительных бактерий. Предложены способ предотвращения, разрушения или эрадикации биопленки, включающей одну или более из бактерий Staphylococcus и Streptococcus, и способ профилактики или лечения инфекции, ассоциированной с биопленкой у субъекта, включающей одну или более из бактерий Staphylococcus и Streptococcus. Способы включают приведение биопленки в контакт с композицией, содержащей измененный литический фермент, включающий домен SH-3 PlySs2, содержащий аминокислотную последовательность SEQ ID NO: 4 или ее вариант, обладающий по меньшей мере 80% идентичностью с SEQ ID NO: 4 и являющийся эффективным для связывания Staphylococcus и Streptococcus в биопленке, и каталитический домен, представляющий собой домен CHAP лизина стрептококковых или стафилококковых фагов. Изобретения позволяют устранять не только зрелые биопленки, но и предотвращать образование биопленок ...

ЭМУЛЬСИЯ СОПОЛИМЕРА ПОЛИТЕТРАФТОРЭТИЛЕНА

... 1. Способ получения эмульсии вода-в-растворителе, включающий следующие стадии:a. растворение сополимера тетрафторэтилена в смешиваемом с водой органическом растворителе;b. обеспечение водной фазы;c. растворение агента, содержащего одно из водорастворимого агента и гидрофобного агента; иd. объединение сополимера тетрафторэтилена с растворенным агентом таким образом, чтобы эмульсия являлась кинетически устойчивой.2. Способ по п. 1, отличающийся тем, что указанный агент представляет собой терапевтический агент.3. Способ по п. 1, отличающийся тем, что указанный агент представляет собой комплекс включения, содержащий гидрофобный агент и гидрофильный комплексообразующий агент.4. Способ по п. 1, отличающийся тем, что указанный агент представляет собой водорастворимый агент, который растворен в водной фазе.5. Способ нанесения на субстрат покрытия, содержащего эмульсию вода-в-растворителе, включающий следующие стадии:a. обеспечение эмульсии вода-в-растворителе, содержащей сополимер тетрафторэтилена ...

ПРЕДОТВРАЩЕНИЕ, РАЗРУШЕНИЕ И ОБРАБОТКА БИОПЛЕНКИ ЛИЗИНОМ БАКТЕРИОФАГА

... 1. Способ предотвращения, разрушения или обработки биопленки грамположительных бактерий, включающий контактирование биопленки с композицией, содержащей полипептид лизина, способный к лизису стафилококков, где биопленку эффективно предотвращают, диспергируют или обрабатывают.2. Способ по п. 1, где полипептид лизина представляет собой PlySs2.3. Способ по п. 2, где полипептид лизина содержит аминокислотную последовательность, представленную на ФИГУРЕ 5 (SEQ ID NO: 1) или ее варианты, имеющие по меньшей мере 80% идентичности с полипептидом ФИГУРЫ 5 (SEQ ID NO: 1), и является эффективным для лизиса грамположительных бактерий в биопленке.4. Способ по п. 1, где композиция дополнительно содержит один или несколько антибиотиков.5. Способ по п. 4, где антибиотик выбирают из даптомицина, ванкомицина и линезолида.6. Способ по п. 1, дополнительно включающий контактирование биопленки с одним или несколькими антибиотиками.7. Способ предотвращения или снижения образования биопленки грамположительных бактерий ...

ПРЕДОТВРАЩЕНИЕ, РАЗРУШЕНИЕ И ОБРАБОТКА БИОПЛЕНКИ ЛИЗИНОМ БАКТЕРИОФАГА

Antibacterial micro-and nanoparticles comprising a chlorhexidine salt, method of production and uses thereof

An antimicrobial micro- or nanoparticles comprising a chlorhexidine salt, wherein the anion in the salt is selected from: phosphates chosen from the homologous series of cyclic metaphosphates which begins with trimetaphosphate, and the homologous series of polyphosphates which begins with pyrophosphate; and the oxoanions and partially hydrogenated oxoanions of nitrogen and sulphur. Preferably the salt is chlorhexidine hexametaphosphate and has a dimension of 20-200nm. Also claimed is the particles in a colloidal suspension, a medical article and a composite material. The antimicrobial micro- or nanoparticles are formed by reacting an aqueous solution comprising chlorhexidine cations with selected anions in a ratio of from 1:100 to 100:1.

COATED BIOLOGICAL DEGRADABLE METALLIC IMPLANT

Methods and devices for cellular transplantation

Devices and methods for transplanting cells in a host body are described. The cell comprises a porous scaffold that allows ingrowth of vascular and connective tissues, a plug or plug system configured for placement within the porous scaffold, and a seal configured to enclose a proximal opening in the porous scaffold. The device may further comprise a cell delivery device for delivering cells into the porous scaffold. The method of cell transplantation comprises a two step process. The device is incubated in the host body to form a vascularized collagen matrix around a plug positioned within the porous scaffold. The plug is then retracted from the porous scaffold, and cells are delivered into the vascularized space created within the porous scaffold.

Coating

H:\tb\Intrwovn\NRPortbl\DCC\TXB86077lI.doc-15/12/2014 The invention relates to a coating composition for an implantable medical device, a method of coating a medical device and a device coated with the composition.

COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES

The present disclosure relates to compounds of Formula II, which are useful for regulating the expression of apolipoprotein A-1 (ApoA-1), and their use for the treatment and prevention of cardiovascular disease and related disease states, including cholesterol-or lipid-related disorders, such as, for example, atherosclerosis. (see formula II) ...

ECHOGENICALLY ENHANCED DEVICE

Devices with enhanced visualization in ultrasound imaging are provided.

ABSORBING ARTICLE

METHODS AND DEVICES FOR CELL TRANSPLANTATION

METHODS AND DEVICES FOR CELL TRANSPLANTATION

ABSORBENT ARTICLE

OSTEOSENTEZ/OSTEOENTEGRASYON HIZLANDIRICI MAGNEZYUM VE/VEYA STRONSİYUM KATKILI KAPLAMALAR

Biofilm prevention, disruption and treatment with bacteriophage lysin

The present invention provides methods for the prevention, control, disruption and treatment of bacterial biofilms with lysin, particularly lysin having capability to kill Staphlococcal bacteria, including drug resistant Staphylococcus aureus, particularly the lysin PlySs2. The invention also provides compositions and methods for use in treatment or modulation of bacterial biofilm(s) and biofilm formation.

BIOFILM PREVENTION, DISRUPTION AND TREATMENT WITH BACTERIOPHAGE LYSIN

The present invention provides methods for the prevention, control, disruption and treatment of bacterial biofilms with lysin, particularly lysin having capability to kill Staphylococcal bacteria, including drug resistant Staphylococcus aureus, particularly the lysin PlySs2. The invention also provides compositions and methods for use in treatment or modulation of bacterial biofilm(s) and biofilm formation.

НОВЫЙ АНАЛОГ ОКСИСТЕРОЛА, OXY149, ИНДУЦИРУЕТ ОСТЕОГЕНЕЗ И СИГНАЛЬНЫЙ ПУТЬ HEDGEHOG И ИНГИБИРУЕТ ЛИПОГЕНЕЗ

... 1. Соединение Oxy149, имеющее формулу Iили его фармацевтически приемлемая соль или сольват.2. Биоактивная композиция, содержащая соединение Oxy149 и фармацевтически приемлемый носитель.3. Биоактивная композиция по п. 2, дополнительно содержащая, по меньшей мере, одно добавочное средство, выбранное из группы, состоящей из паратиреоидного гормона, фторида натрия, инсулиноподобного фактора роста I (ILGF-I), инсулиноподобного фактора роста II (ILGF-II), трансформирующего ростового фактора бета (TGF-β), ингибитора цитохрома Р450, остеогенного простаноида, BMP 2, BMP 4, BMP 7, BMP 14 и/или противорезорбтивного средства.4. Способ лечения субъекта, имеющего заболевание кости, остеопороз или перелом кости, включающий введение субъекту эффективного количества биоактивной композиции по п. 2.5. Способ по п. 4, включающий введение субъекту биоактивной композиции в терапевтически эффективной дозе в эффективной лекарственной форме с подобранным интервалом с целью увеличения костной массы.6. Способ по ...

Novel nitric oxide-eluting bioresorbable stents for percutananeous coronary interventions

Medical device having surface lubricity in wet state

Disclosed is a medical device wherein a metal base and a surface lubricating layer are fixed with each other more firmly. The medical device permanently exhibits excellent surface lubricity when in use. Specifically disclosed is a medical device (10) which has a lubricating surface when wet, and is characterized by comprising a base layer (1) which is composed of a metal material, an intermediate layer (2) which covers at least a part of the base layer (1) and is composed of a compound that has a plurality of thiol groups in each molecule, and a surface lubricating layer (3) which covers the surface of the intermediate layer (2) and is composed of a hydrophilic polymer that has a reactive functional group. The medical device (10) is also characterized in that the surface lubricating layer (3) is bonded to the base layer (1) via the intermediate layer (2) by reacting the compound having thiol groups with the hydrophilic polymer.

Multi-function dressing structure for negative-pressure therapy

C0~f Systems, methods, and apparatuses for forming a multi-function core for a dressing are described. The multi-function core includes a contact layer configured to be positioned adjacent to a tissue site, a wicking layer adjacent to the contact layer, an ion exchange layer adjacent to the wicking layer, an absorbing layer adjacent to the ion exchange layer, a blocking layer adjacent to the absorbing layer, and an odor-absorbing layer adjacent to the blocking layer. The contact layer, the wicking layer, the ion exchange layer, the absorbing layer, the blocking layer, and the odor-absorbing layer are coextensive and formed from a plurality of fibers disposed in a fibrous web. Methods of manufacturing the multi-function core are also described.

Echogenically enhanced device

Devices with enhanced visualization in ultrasound imaging are provided.

PEEL AND PLACE DRESSING FOR NEGATIVE-PRESSURE THERAPY

A dressing for treating a tissue site with negative pressure may comprise a cover having an adhesive, a manifold, a perforated polymer film, and a perforated silicone gel having a treatment aperture. The cover, the manifold, the perforated polymer film, and the perforated silicone gel may be assembled in a stacked relationship with the cover and the perforated silicone gel enclosing the manifold. The perforated polymer film may be at least partially exposed through the treatment aperture, and at least some of the adhesive may be exposed through the perforated silicone around the treatment aperture.

LIQUID INJECTABLE COPOLYMER

The invention provides liquid injectable copolymers of TMC and HTMC that are degradable in vivo. Degradation can be tailored by adjusting the amount of HTMC in the copolymer, the initial molecular weight of the copolymer, and the characteristics of the initiator used in its preparation. Specifically, the degradation rate increases as the amount of HTMC incorporated into the copolymer increases, as the molecular weight of the copolymer decreases, and as the hydrophobicity of the initiator decreases. Moreover, the degradation yields products such as glycerol and carbon dioxide that are non-toxic in vivo, and which will not cause a substantive change in tissue pH upon implantation in vivo. The copolymers may be used in applications such as drug delivery and as coatings.

ABSORBABLE STENT HAVING A COATING FOR CONTROLLING DEGRADATION OF THE STENT AND MAINTAINING PH NEUTRALITY

A biocompatible metallic material may be configured into any number of implantable medical devices, including intraluminal stents. The biocompatible metallic material may comprise a magnesium alloy. The magnesium alloy implantable medical device may be designed to degrade over a given period of time. In order to control the degradation time, the device may be coated or otherwise have affixed thereto one or more coatings, one of which comprises a material for controlling the degradation time and maintain a pH neutral environment proximate the device. Additionally, therapeutic agents may be incorporated into one or more of the coatings on the implantable medical device.

METHODS AND DEVICES FOR CELL TRANSPLANTATION

Medical materials

An object of the present invention provides a medical material which consists of firmly anchoring a compound, being capable of inhibiting a blood coagulation reaction in both the primary hemostasis step associated with platelets and the blood clot formation step associated with blood coagulation factors, to a surface thereof by maintaining an anti blood-coagulation activity. The present invention provides a medical material which consists of firmly anchoring a hydrophilic polymer compound formed by binding a compound represented by the following formula (I) and a copolymer of monomers selected from the group consisting of ethylene glycol, vinyl acetate, vinyl pyrrolidone, propylene glycol, vinyl alcohol and siloxane to a surface.

BLOCK COPOLYMERS OF ACRYLATES AND METHACRYLATES WITH FLUOROALKENES

A block copolymer comprising a fluorinated block and a non-fluorinated block and method of making the block copolymer are provided. Also provided herein are a coating on an implantable device comprising the block copolymer and method of using the implantable device.

METHOD OF INHIBITING VASCULAR INTIMAL HYPERPLASIA USING STENT

A method of inhibiting vascular intimal hyperplasia including: placing a stent within a blood vessel, the stent having a stent body of a cylindrical configuration having outer and inner surfaces with a diamond-like thin film coated on the surfaces, a first coated layer coating at least the outer surface of the stent body, the first coated layer being prepared of a first composition comprising a biodegradable polymer and a vascular intimal hyperplasia inhibitor of a kind, comprising argatroban, which does not inhibit proliferation of endothelial cells, the weight composition ratio of the polymer to the vascular intimal hyperplasia inhibitor being within the range of 8:2 to 7:3, and a second coated layer; and causing argatroban to be released from the stent to thereby inhibit the vascular intimal hyperplasia without inhibiting proliferation of endothelial cells.

Block copolymers of acrylates and methacrylates with fluoroalkenes

A block copolymer comprising a fluorinated block and a non-fluorinated block and method of making the block copolymer are provided. Also provided herein are a coating on an implantable device comprising the block copolymer and method of using the implantable device.

Coated Implantable Medical Device and Coating Method

An intracardiac pacing system comprising a fixation element for fixing the intracardiac pacing system to body tissue is disclosed. The fixation element comprises a metallic material, and is at least partially coated with a metal-ion release inhibiting material. Also, a method for coating at least part of an intracardiac pacing system is disclosed.

FEMININE HYGIENE ABSORBENT ARTICLES COMPRISING WATER-ABSORBING COMPOSITES

This invention relates to a feminine hygiene absorbent article comprising water-absorbing composites obtainable by foaming an aqueous mixture comprising at least one monoethylenically unsaturated monomer bearing acid groups, at least one crosslinker, at least one initiator and at least one surfactant, contacting the foam obtained with at least one web of synthetic fibers and polymerizing, to the composites themselves and to their use for absorbing aqueous fluids. 1. A feminine hygiene absorbent article comprising a water-absorbing composite comprising at least one superabsorbent foam layer and at least one web layer , the web composed of synthetic fiber;wherein the web is completely penetrated by the foam; andwherein the web layer swells one-dimensionally when in contact with an aqueous fluid.2. The feminine hygiene absorbent article of wherein the foam comprises at least one polymerized monoethylenically unsaturated monomer bearing at least one acid group.3. The feminine hygiene absorbent article according to wherein the acid groups of the polymerized monoethylenically unsaturated monomer are at least partly in a neutralized state.4. The feminine hygiene absorbent article of wherein the foam comprises at least one polymerized crosslinker.5. The feminine hygiene absorbent article of wherein the web is mechanically and/or thermally consolidated.6. The feminine hygiene absorbent article of wherein the foam is coated with at least one salt of a multivalent cation.7. A feminine hygiene absorbent article of claim 1 , wherein said composite is obtainable by foaming an aqueous mixture comprising at least one monoethylenically unsaturated monomer bearing acid groups claim 1 , at least one crosslinker claim 1 , at least one initiator and at least one surfactant claim 1 , contacting the resulting foam with a web of synthetic fibers claim 1 , and polymerizing.8. The feminine hygiene absorbent article according to wherein the composite is coated with at least one salt of a ...

УСТРОЙСТВО С ПОВЫШЕННОЙ ЭХОГЕННОСТЬЮ

FIELD: medicine. SUBSTANCE: invention relates to medical equipment, namely to means with higher echogenicity for obtaining ultrasonic images. Intervention device contains intervention device, for which obtained is ultrasonic image, which has external surface, containing one or more topographic irregularities of in other cases smooth surface of intervention device and polymer film, which is in tight contact with external surface and closed at least part of one or more topographic irregularities, with tension of polymer film and resonance characteristic of polymer film are adjustable. In method of increasing echogenicity one or more topographic irregularities of in other cases smooth external surface of intervention film is (are) formed, with polymer film being placed in tight contact with external surface, with tension of polymer film being adjustable. Echogenic response of intervention device is regulated by means of device visualisation of device and regulation of polymer film tension, with adjustment of tension changing resonance characteristics of polymer film, covering one or more topographic irregularities. EFFECT: application of invention makes it possible to improve visibility of objects in ultrasound. 13 cl, 4 dwg РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 2 556 569 C1 (51) МПК A61B 8/08 (2006.01) A61L 31/14 (2006.01) A61K 49/22 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ОПИСАНИЕ (21)(22) Заявка: ИЗОБРЕТЕНИЯ К ПАТЕНТУ 2013154091/14, 07.05.2012 (24) Дата начала отсчета срока действия патента: 07.05.2012 (72) Автор(ы): КАЛЛИ Эдвард Х. (US), ФЛЮРИ Кейт М. (US) (73) Патентообладатель(и): В.Л. ГОР ЭНД АССОШИЕЙТС, ИНК. (US) Приоритет(ы): (30) Конвенционный приоритет: R U 06.05.2011 US 61/483,094 (45) Опубликовано: 10.07.2015 Бюл. № 19 2007066863 A1, 22.03.2007. US 2005137664 A1, 23.06.2005. US 2003009100 A1, 09.01.2003. US 4869259 A, 26.09.1989. RU 2389451 C2, 20.05.2010 (85) Дата начала рассмотрения заявки PCT на национальной фазе: 06.12.2013 ...

A method and apparatus for applying a bone attachment coating

Materials and methods

The invention relates to methods of controlling orientation of direct covalent binding of a peptide to a polymer substrate surface, to surfaces with peptides directly covalently bound thereto in a manner where the orientation of binding is controlled as well as to devices comprising such substrates. In particular the invention relates to A method of controlling predominant orientation of direct covalent binding of one or more peptides to a polymer substrate surface comprising: (a) exposing the surface to energetic ion treatment to generate a plurality of activated sites comprising reactive radical species; (b) incubating the surface with one or more peptide/s that exhibit or can be induced to exhibit a dipole moment and manipulating the electric field environment and/or charge of said surface and/or of said peptide/s during said incubating; wherein predominant orientation of direct covalent binding of said peptide/s to said surface is thereby controlled.

Soluble bacterial and fungal proteins and methods and uses thereof in inhibiting and dispersing biofilm

The present disclosure relates to methods of treating or preventing a biofilm-related infection and methods of preventing and treating biofilm formation on indwelling medical devices, implants, and non-medical surfaces comprising administering at least one soluble microbial protein that is encoded by an exopolysaccharide biosynthetic operon or functional gene cluster, wherein the protein comprises a glycosyl hydrolase domain. The present disclosure further provides particular soluble glycosyl hydrolases and compositions thereof.

Polytetrafluoroethylene co-polymer emulsions

The present disclosure is directed to a class of fluorinated copolymers, such as PTFE copolymers, that can be dissolved in low toxicity solvents, such as Class III Solvents, and that enable the creation of stable water-in-solvent emulsions comprising the fluorinated copolymers dissolved in a low toxicity solvents and a hydrophilic agent (e.g., a therapeutic agent) dissolved in an aqueous solvent, such as water or saline.

FACTOR XII INHIBITORS FOR THE ADMINISTRATION WITH MEDICAL PROCEDURES COMPRISING CONTACT WITH ARTIFICIAL SURFACES

Abstract 5 An inhibitor of FXII/FXlla for the prevention of the formation and/or stabilization of thrombi during and/or after a medical procedure performed on a human or animal subject comprising contacting blood of said human or animal subject with artificial surfaces, wherein said inhibitor of FXII/FXlla is administered before and/or during and/or after said medical procedure.

HYPERTONIC ANTIMICROBIAL THERAPEUTIC COMPOSITIONS

Therapeutic compositions, primarily for topical application, and methods of making and using the composition. Pharmaceutical compositions formulated for specific forms of administration are also provided.

DRY EYE TREATMENT DEVICES AND METHODS

Devices can be implanted in an eye to treat a dry eye condition. The devices include a body defining a lumen and having first and second ends and external and lumenal surfaces. The body has a length sufficient to provide fluid communication between the anterior chamber and tear film of the eye through the lumen when the device is implanted in the sclera. In some embodiments, the device is filterless. In some embodiments, a filter is included. The dry eye treatment devices provided herein prevent bacterial ingress, provide outflow resistance to retain a normal intraocular pressure, and provide moisture (e.g., aqueous humor) to an otherwise dry eye. Methods of treating a dry eye condition wherein the device is implanted in the sclera of an afflicted eye are also described.

IRRIGATION RESISTANT COMPOSITIONS FOR REGENERATION OF HARD TISSUES AND METHODS AND KITS OF USING THE SAME

An irrigation resistant bone repair composition including a biocompatible or bioactive bone repair material and a mixture of non-random poly(oxyalkylene) block copolymers is described. Also, methods for treating a bone having a bone gap or a bone defect with the composition including a biocompatible or bioactive bone repair material and a mixture of non-random poly(oxyalkylene) block copolymers are also provided. Also, kits including the irrigation resistant bone repair composition includ¬ ing a biocompatible or bioactive bone repair material and a mixture of non-random poly(oxyalkylene) block copolymers are described.

METHODS AND DEVICES FOR CELLULAR TRANSPLANTATION

Devices and methods for transplanting cells in a host body are described. The cell comprises a porous scaffold that allows ingrowth of vascular and connective tissues, a plug or plug system configured for placement within the porous scaffold, and a seal configured to enclose a proximal opening in the porous scaffold. The device may further comprise a cell delivery device for delivering cells into the porous scaffold. The method of cell transplantation comprises a two step process. The device is incubated in the host body to form a vascularized collagen matrix around a plug positioned within the porous scaffold. The plug is then retracted from the porous scaffold, and cells are delivered into the vascularized space created within the porous scaffold.

MULTILAYER MEDICAL BALLOON

An expandable medical balloon including an inner layer formed of a poly(ether-block-amide) copolymer and an outer layer formed of a polyamide, the expandable medical balloon having a burst strength of greater than 50,000 psi, and to methods of making and using the same.

Absorbent article having a lotioned top sheet

GOLD NANOROD-COUPLED TITANIA NANOTUBE AND MANUFACTURING METHOD THEREOF

The present invention relates to a gold nanorod-coupled titania nanotube and a manufacturing method thereof and, more specifically, to a gold nanorod-coupled titania nanotube, and to a method for manufacturing a gold nanorod-coated titania nanotube. The method comprises the following steps: forming a titania nanotube layer on the surface of a titanium material; substituting a SH group on the surface of the titania nanotube layer; and coupling the gold nanorod to the SH group on the surface of the titania nanotube. The method is capable of preventing unnecessary administration, and minimizing side effects due to unnecessary administration, by discharging drugs during a desired period for the desired time. COPYRIGHT KIPO 2016 ...

ABSORBENT ARTICLE

Compositions and Methods for Preventing and Ameliorating Fouling on Medical Surfaces

A composition which can be detached from a surface which composition serves the purpose of impeding the detrimental effects of adherent fouling from the environment surrounding the surface. The composition may be single layered or multilayered as to allow for removal or attachment at multiple time points and/or over different durations. These time points may correspond to a progression to a negative effect of fouling, such as progression from biofilm maturation to bacterial detachment into host tissue for indwelling medical devices, or a predetermined threshold of tolerable fouling effect, such as blockage of a foley catheter by organic and inorganic encrustation material. This composition does not contribute to the function of the surface or the object whose boundaries are defined by the surface, such that its attachment or detachment is primarily aimed at mitigating the effects of fouling.

Ion exchange absorbent systems, apparatuses, and methods

Systems, methods, and apparatuses for increasing liquid absorption are described. Some embodiments may include a dressing having an absorbent layer containing super-absorbent material as well as ionic-exchange media (IEM). In some embodiments, the absorbent layer may include absorbent fibers. The absorbent fibers may each include a super-absorbent core surrounded by a water-permeable layer onto which ionic-exchange media (IEM) may be grafted. As liquid comes into contact with the IEM, its ionic nature may be reduced, therefore protecting the absorbent qualities of the super-absorbent material.

Liquid injectable copolymer

The invention provides liquid injectable copolymers of TMC and HTMC that are degradable in vivo. Degradation can be tailored by adjusting the amount of HTMC in the copolymer, the initial molecular weight of the copolymer, and the characteristics of the initiator used in its preparation. Specifically, the degradation rate increases as the amount of HTMC incorporated into the copolymer increases, as the molecular weight of the copolymer decreases, and as the hydrophobicity of the initiator decreases. Moreover, the degradation yields products such as glycerol and carbon dioxide that are non-toxic in vivo, and which will not cause a substantive change in tissue pH upon implantation in vivo. The copolymers may be used in applications such as drug delivery and as coatings.

Medizinisches Instrument

Medizinisches Instrument, das in einen menschlichen oder tierischen Körper einführbar ist, wobei das medizinische Instrument einen Instrumentenkörper mit einer Oberfläche aufweist, die mit dem menschlichen oder tierischen Körper in Kontakt kommen kann. Das medizinische Instrument zeichnet sich dadurch aus, dass der Instrumentenkörper im Oberflächenbereich mit einem immobilisierten aktiven MR-Marker versehen ist.

Coating

Antibacterial micro-and nanoparticles comprising a chlorhexidine salt, method of production and uses thereof

Novel polypeptides and medical uses thereof

USE OF BACTERIAL POLYSACCHARIDE FOR BIO FILM INHIBITION

BIOFILM PREVENTION, DISRUPTION AND TREATMENT WITH BACTERIOPHAGE LYSIN

The present invention provides methods for the prevention, control, disruption and treatment of bacterial biofilms with lysin, particularly lysin having capability to kill Staphlococcal bacteria, including drug resistant Staphylococcus aureus, particularly the lysin PlySs2. The invention also provides compositions and methods for use in treatment or modulation of bacterial biofilm(s) and biofilm formation.

Analogs of pitutary adenylate cyclase-activating polypeptide (PACAP) and methods for their use

This invention relates to novel analogs of pituitary adenylate cyclase- activating polypeptide (PACAP), which are agonists for the PACAP/vasoactive intestinal peptide (VIP) receptors: PAC1, VPAC1 and VPAC2 receptors. These PACAP analogs can be used as prophylactic/therapeutic agents for a wide range of medical disorders, including (but not limited to) cancer and autoimmune disease. These PACAP analogs can be coupled to suitable radionuclides and used in the localization, diagnosis and treatment of disseminated cancers and metastatic tumors, or coupled to small molecule therapeutics and used as vectors for targeted drug delivery. This invention also provides pharmaceutical compositions of one or more PACAP-like compounds of the invention either alone or in combination with one or more other prophylactic/therapeutic agents.

Implants with absorbable and non-absorbable features for the treatment of female pelvic conditions

Described are methods, devices, and systems related to implants for the treatment of a female pelvic condition. The implants include absorbable and non-absorbable materials and can be introduced into the pelvic area transvaginally. Meshes of the invention provide benefits relating to improved tissue integration into the mesh, reduced infection likelihood, improved patient comfort following implantation, or combinations of thereof.

Sustained drug-releasing stent

A stent includes a stent body of a cylindrical configuration having outer and inner surfaces, a first coated layer coating at least the outer surface, and 5 a second coated layer coating substantially completely over the first coated layer. The first coated layer is prepared of a first composition comprising a polymer and a vascular intimal hyperplasia inhibitor (preferably argatroban) of a kind, which does not inhibit proliferation of endothelial cells, the weight compositional ratio of the polymer to the inhibitor being within the range of 8 : 2 to 3 : 7. On 10 the other hand, the second coated layer is prepared of a polymer alone or a second composition comprising a polymer and a drug, the weight compositional ratio of the drug to 80 % by weight of the polymer being less than 20 % by weight.

Biofilm prevention, disruption and treatment with bacteriophage lysin

The present invention provides methods for the prevention, control, disruption and treatment of bacterial biofilms with lysin, particularly lysin having capability to kill Staphlococcal bacteria, including drug resistant Staphylococcus aureus, particularly the lysin PlySs2. The invention also provides compositions and methods for use in treatment or modulation of bacterial biofilm(s) and biofilm formation.

Dry eye treatment devices and methods

Devices can be implanted in an eye to treat a dry eye condition. The devices include a body defining a lumen and having first and second ends and external and lumenal surfaces. The body has a length sufficient to provide fluid communication between the anterior chamber and tear film of the eye through the lumen when the device is implanted in the sclera. In some embodiments, the device is filterless. In some embodiments, a filter is included. The dry eye treatment devices provided herein prevent bacterial ingress, provide outflow resistance to retain a normal intraocular pressure, and provide moisture (e.g., aqueous humor) to an otherwise dry eye. Methods of treating a dry eye condition wherein the device is implanted in the sclera of an afflicted eye are also described.

BIOFILM PREVENTION, DISRUPTION AND TREATMENT WITH BACTERIOPHAGE LYSIN

The present invention provides methods for the prevention, control, disruption and treatment of bacterial biofilms with lysin, particularly lysin having capability to kill Staphlococcal bacteria, including drug resistant Staphylococcus aureus, particularly the lysin PlySs2. The invention also provides compositions and methods for use in treatment or modulation of bacterial biofilm(s) and biofilm formation.

Absorbent article

The purpose of the present invention is to provide an absorbent article in which a top sheet (2) does not have the conventional concavo-convex shape, and the top sheet (2) feels dry and does not feel sticky even after absorbing menstrual blood having a high viscosity. This absorbent article has a liquid-permeable top sheet (2), a liquid-impermeable back sheet (6), and an absorbent (3) disposed between the liquid-permeable top sheet (2) and the liquid-impermeable back sheet (6), wherein the liquid-permeable top sheet (2) has a grammage of 5 to 30 g/m ...

PEPTIDE-COATED CALCIUM PHOSPHATE PARTICLES

The invention features methods and compositions for (i) controlling the amount of peptide bound to calcium phosphate particles; and (ii) for tightly binding peptide to the surface of calcium phosphate particles. The methods and compositions can be useful for preparing implants useful for promoting bone deposition at the site of implantation, and for repairing a variety of orthopedic conditions.

ION EXCHANGE ABSORBENT SYSTEMS, APPARATUSES, AND METHODS

Systems and apparatuses for increasing liquid absorption are described. Some embodiments may include a dressing having an absorbent layer containing super-absorbent material as well as ionic-exchange media (IEM). In some embodiments, the absorbent layer may include absorbent fibers. The absorbent fibers may each include a super-absorbent core surrounded by a water-permeable layer onto which ionic-exchange media (IEM) may be grafted. As liquid comes into contact with the IEM, its ionic nature may be reduced, therefore protecting the absorbent qualities of the super-absorbent material.

COATING

The invention relates to a coating composition for an implantable medical device, a method of coating a medical device and a device coated with the composition.

METHODS AND DEVICES FOR CELLULAR TRANSPLANTATION

Novel Peptide Compound for Inhibiting Restenosis and Promoting Re-Endothelialization and Method for Preparing the Same

Provided are a peptide compound prepared by additional synthesis in a drug having an effect of inhibiting restenosis, a composition for inhibiting restenosis and promoting re-endothelialization including the peptide compound, and a stent having a surface coated by using the composition, in order to overcome a restenosis problem in the stent. 2. The stent of claim 1 , wherein the stent is a stent for preventing or treating a cardiovascular disease. This application is a divisional of U.S. patent application Ser. No. 14/741,949, filed Jun. 17, 2015, which claims priority to Korean Patent Application No. 10-2014-0074700, filed Jun. 19, 2014, the disclosures of which are each hereby incorporated by reference in their entirety.The Sequence Listing associated with this application is filed in electronic format via EFS-Web and is hereby incorporated by reference into the specification in its entirety. The name of the text file containing the Sequencing Listing is 154859DIV_ST25txt. The size of the text file is 580 bytes, and the text file was created on Apr. 14, 2016.The following disclosure relates to a peptide compound for inhibiting restenosis and promoting re-endothelialization and a method for preparing the same.In accordance with the recent trend of an aging society, a coronary artery disease such as angina pectoris, myocardial infarction, or the like, has increased at a rapid rate in adults in Korea over the last 10 years, and is the highest cause of death except for cancer. The coronary artery disease is a disease that occurs in blood vessels surrounding the heart, and causes blood supply disorder in the heart muscle. The most common cause of the coronary artery disease is arteriosclerosis. When plaque made by a combination of cholesterol and other fats accumulate in coronary arteries, and various other components in blood are correspondingly increased, which cause coronary stenosis, and accordingly, blood supply to the heart muscle is reduced, which results in ...

BIODEGRADABLE COATINGS FOR IMPLANTABLE MEDICAL DEVICES

Biodegradable coatings for implantable medical devices are disclosed.

Oleophilic Lubricated Catheters

A medical device wherein the device has an outer surface coated with an oleophilic lubricous coating or the device is formed from a mixture including a polymer and an oleophilic compound.

Eye treatment devices and methods

Devices can be implanted in an eye to treat a dry eye condition. The devices include a body defining a lumen and having first and second ends and external and lumenal surfaces. The body has a length sufficient to provide fluid communication between the anterior chamber and tear film of the eye through the lumen when the device is implanted in the sclera. In some embodiments, the device is filterless. In some embodiments, a filter is included. The dry eye treatment devices provided herein prevent bacterial ingress, provide outflow resistance to retain a normal intraocular pressure, and provide moisture (e.g., aqueous humor) to an otherwise dry eye. Methods of treating a dry eye condition wherein the device is implanted in the sclera of an afflicted eye are also described.

Biofilm prevention, disruption and treatment with bacteriophage lysin

The present invention provides methods for the prevention, control, disruption and treatment of bacterial biofilms with lysin, particularly lysin having capability to kill Staphlococcal bacteria, including drug resistant Staphylococcus aureus, particularly the lysin PlySs2. The invention also provides compositions and methods for use in treatment or modulation of bacterial biofilm(s) and biofilm formation.

ПРЕДОТВРАЩЕНИЕ, РАЗРУШЕНИЕ И ОБРАБОТКА БИОПЛЕНКИ ЛИЗИНОМ БАКТЕРИОФАГА

Группа изобретений относится к способам и композициям для предотвращения, контроля и разрушения бактериальных биопленок с использованием лизина, имеющего способность к лизису стафилококковых и стрептококковых бактерий, включая резистентные к лекарственным средствам. Способы включают контактирование биопленки, включающей одну или несколько из бактерий Staphylococcus или Streptococcus, с композицией, содержащей эффективное количество полипептида лизина, содержащего аминокислотную последовательность SEQ ID NO: 1 или ее варианты, имеющие по меньшей мере 80% идентичности с полипептидом с SEQ ID NO: 1, и являющегося эффективным для лизиса стафилококковых и стрептококковых бактерий в биопленке, причем биопленку эффективно диспергируют или обрабатывают. Изобретения позволяют устранять не только зрелые биопленки, но и предотвращать образование биопленок, при этом применяемый полипептид лизина демонстрирует высокую активность при более низких концентрациях (1X МПК) в сравнении с отсутствием активности ...

Отслаиваемый и размещаемый на месте перевязочный материал для терапии при отрицательном давлении

МЕДИЦИНСКИЕ МАТЕРИАЛЫ

... 1. Медицинский материал, включающий гидрофильное полимерное соединение, иммобилизованное на его поверхности, где указанное гидрофильное полимерное соединение представляет собой такое соединение, в которомсоединение общей формулы (I) исополимер мономеров, выбранных из группы, состоящей из этиленгликоля, винилацетата, винилпирролидона, пропиленгликоля, винилового спирта и силоксана, связаны между собой:где Rпредставляет собой группу (2R,4R)-4-алкил-2-карбоксипиперидино; Rпредставляет собой фенильную группу или группу конденсированного полициклического соединения, где указанная группа конденсированного полициклического соединения может быть необязательно замещена низшей алкильной группой, низшей алкоксигруппой или аминогруппой, которая замещена низшей алкильной группой.2. Медицинский материал по п. 1, где указанный сополимер представляет собой силикон, модифицированный полиэфиром.3. Медицинский материал по п. 1 или 2, где указанное соединение общей формулы (I) представляет собой (2R,4R)-4- ...

Composition

Medical device having surface lubricity in wet state

Disclosed is a medical device wherein a metal base and a surface lubricating layer are fixed with each other more firmly. The medical device permanently exhibits excellent surface lubricity when in use. Specifically disclosed is a medical device (10) which has a lubricating surface when wet, and is characterized by comprising a base layer (1) which is composed of a metal material, an intermediate layer (2) which covers at least a part of the base layer (1) and is composed of a compound that has a plurality of thiol groups in each molecule, and a surface lubricating layer (3) which covers the surface of the intermediate layer (2) and is composed of a hydrophilic polymer that has a reactive functional group. The medical device (10) is also characterized in that the surface lubricating layer (3) is bonded to the base layer (1) via the intermediate layer (2) by reacting the compound having thiol groups with the hydrophilic polymer.

Coating

Biofilm prevention, disruption and treatment with bacteriophage lysin

The present invention provides methods for the prevention, control, disruption and treatment of bacterial biofilms with lysin, particularly lysin having capability to kill Staphlococcal bacteria, including drug resistant Staphylococcus aureus, particularly the lysin PlySs2. The invention also provides compositions and methods for use in treatment or modulation of bacterial biofilm(s) and biofilm formation.

IMPLANTS WITH ABSORBABLE AND NON-ABSORBABLE FEATURES FOR THE TREATMENT OF FEMALE PELVIC CONDITIONS

Described are methods, devices, and systems related to implants for the treatment of a female pelvic condition. The implants include absorbable and non 5 absorbable materials and can be introduced into the pelvic area transvaginally. Meshes of the invention provide benefits relating to improved tissue integration into the mesh, reduced infection likelihood, improved patient comfort following implantation, or combinations of thereof.

MULTI-FUNCTION DRESSING STRUCTURE FOR NEGATIVE-PRESSURE THERAPY

Systems and apparatuses for forming a multi-function core for a dressing are described. The multi-function core includes a contact layer configured to be positioned adjacent to a tissue site, a wicking layer adjacent to the contact layer, an ion exchange layer adjacent to the wicking layer, an absorbing layer adjacent to the ion exchange layer, a blocking layer adjacent to the absorbing layer, and an odor-absorbing layer adjacent to the blocking layer. The contact layer, the wicking layer, the ion exchange layer, the absorbing layer, the blocking layer, and the odor-absorbing layer are coextensive and formed from a plurality of fibers disposed in a fibrous web. Methods of manufacturing the multi-function core are also described.

POLYTETRAFLUOROETHYLENE CO-POLYMER EMULSIONS

The present disclosure is directed to a class of fluorinated copolymers, such as PTFE copolymers, that can be dissolved in low toxicity solvents, such as Class III Solvents, and that enable the creation of stable water-in-solvent emulsions comprising the fluorinated copolymers dissolved in a low toxicity solvents and a hydrophilic agent (e.g., a therapeutic agent) dissolved in an aqueous solvent, such as water or saline.

OLEOPHILIC LUBRICATED CATHETERS

A urinary catheter, comprising: a catheter tube having an outer surface; and an oleophilic composition comprising oleic acid and glycerol esters thereof for use as a lubricant or lubricious composition for the urinary catheter disposed on the outer surface of the catheter tube, wherein the lubricant or lubricious composition has a coefficient of friction of less than 0.45.

PROGESTERONE-CONTAINING COMPOSITIONS AND DEVICES

The present invention is directed to progesterone-containing compositions and devices that can maintain opening of a body passageway. One aspect of the invention provides a therapeutically effective (e.g., relaxative, anti-oxidative, anti-restenotic, anti-angiogenic, and/or anti -thrombotic) composition or formulation containing progesterone and optionally vitamin E. Another aspect of the invention provides a drug eluting device with at least one coating layer comprising a progesterone composition that can minimize or eliminate inflammation, thrombosis, restenosis, neo-intimal hyperplasia, rupturing of vulnerable plaque, and/or other effects related to device implantation, treatment, or interaction. Other aspects of the invention provide for methods of using such compositions, formulations, and devices.

Tumor ablation system

Oleophilic lubricated catheters

A medical device wherein the device has an outer surface coated with an oleophilic lubricous coating or the device is formed from a mixture including a polymer and an oleophilic compound.

Surface-Independent, Surface-Modifying, Multifunctional Coatings and Applications Thereof

The present invention provides a surface-independent surface-modifying multifunctional biocoating and methods of application thereof. The method comprises contacting at least a portion of a substrate with an alkaline solution comprising a surface-modifying agent (SMA) such as dopamine so as to modify the substrate surface to include at least one reactive moiety. In another version of the invention, a secondary reactive moiety is applied to the SMA-treated substrate to yield a surface-modified substrate having a specific functionality.

ЖЕНСКИЕ ГИГИЕНИЧЕСКИЕ АБСОРБИРУЮЩИЕ ИЗДЕЛИЯ, СОДЕРЖАЩИЕ АБСОРБИРУЮЩИЕ ВОДУ КОМПОЗИЦИОННЫЕ МАТЕРИАЛЫ

... 1. Женское гигиеническое абсорбирующее изделие, содержащее абсорбирующий воду композиционный материал, содержащий, по меньшей мере, один слой суперабсорбирующего вспененного материала и, по меньшей мере, один слой полотна, при этом полотно сформировано из синтетического волокна и имеет основную массу не более, чем 200 г/ми толщину не более, чем 5 мм.2. Женское гигиеническое абсорбирующее изделие по п. 1, отличающееся тем, что полотно полностью проникает во вспененный материал.3. Женское гигиеническое абсорбирующее изделие по п. 1, отличающееся тем, что вспененный материал полностью проникает в полотно.4. Женское гигиеническое абсорбирующее изделие по любому из пп. 1-3, отличающееся тем, что вспененный материал содержит, по меньшей мере, один полимеризованный моноэтилен-ненасыщенный мономер, несущий, по меньшей мере, одну кислотную группу.5. Женское гигиеническое абсорбирующее изделие по п. 4, отличающееся тем, что кислотные группы полимеризованного моноэтилен-ненасыщенного мономера находятся ...

УСТРОЙСТВО С ПОВЫШЕННОЙ ЭХОГЕННОСТЬЮ

... 1. Интервенционное устройство с повышенной эхогенностью, содержащее:(a) интервенционное устройство, для которого должно быть получено ультразвуковое изображение, причем упомянутый инструмент или устройство имеет поверхность с одним или более отверстиями; и(b) полимерную пленку, находящуюся в тесном контакте с поверхностью упомянутого устройства, закрывая по меньшей мере участок одного или более отверстий.2. Интервенционное устройство с повышенной эхогенностью по п.1, в котором полностью указанные одно или более отверстий закрыты полимерной пленкой.3. Интервенционное устройство с повышенной эхогенностью по п.1, в котором поверхность упомянутого устройства содержит множество отверстий.4. Интервенционное устройство с повышенной эхогенностью по п.1, в котором полимерная пленка охватывает поверхность упомянутого устройства.5. Интервенционное устройство с повышенной эхогенностью по п.1, в котором натяжение полимерной пленки, охватывающей поверхность упомянутого устройства, регулируется.6. Интервенционное ...

Silicone gel-coated wound dressing

Stent for controlled drug release

Compounds for the prevention and treatment of cardiovascular diseases

The present disclosure relates to compounds, which are useful for regulating the expression of apolipoprotei A-I (ApoA-l), and their use for the treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis.

Absorbent article

The purpose of the present invention is to provide an absorbent article in which a top sheet (2) does not have the conventional concavo-convex shape, and the top sheet (2) feels dry and does not feel sticky even after absorbing menstrual blood having a high viscosity. This absorbent article has a liquid-permeable top sheet (2), a liquid-impermeable back sheet (6), and an absorbent (3) disposed between the liquid-permeable top sheet (2) and the liquid-impermeable back sheet (6), wherein the liquid-permeable top sheet (2) has a grammage of 5 to 30 g/m ...

Sustained drug-releasing stent

Oleophilic lubricated catheters

A medical device wherein the device has an outer surface coated with an oleophilic lubricous coating or the device is formed from a mixture including a polymer and an oleophilic compound.

PEEL AND PLACE DRESSING FOR NEGATIVE-PRESSURE TREATMENT

A dressing for treating a tissue site with negative pressure may comprise a tissue interface comprising a three-dimensional textile of polyester fibers and a polymer coating on the polyester fibers. In some examples, the three-dimensional textile may be a three-dimensional weave of polyester fibers, and the polymer coating may be hydrophobic. In more particular embodiments, the polymer coating may be silicone or polyethylene, for example. The dressing may additionally include a drape disposed over the tissue interface and a port fluidly coupled to the tissue interface through the drape. The tissue interface may be applied over a tissue site, and therapeutic levels of negative pressure may be applied to the tissue site through the tissue interface.

ANTIBACTERIAL MICRO- AND NANOPARTICLES COMPRISING A CHLORHEXIDINE SALT, METHOD OF PRODUCTION AND USES THEREOF

Antimicrobial micro- or nanoparticles comprising a chlorhexidine salt and an anion, and a method of making the antimicrobial micro-or nanoparticle, are disclosed. The anion in the salt is selected from oxoanions and partially hydrogenated oxoanions of phosphorus, carbon, nitrogen, and sulfur.

COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULARDISEASES

The present disclosure relates to compounds, which are useful for regulat ing the expression of apolipoprotei.pi. A-I (ApoA-l), and their use for the treatment and prevention of cardiovascular disease and related disease state s, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis.

FACTOR XII INHIBITORS FOR THE ADMINISTRATION WITH MEDICAL PROCEDURES COMPRISING CONTACT WITH ARTIFICIAL SURFACES

An inhibitor of FXII/FXIla for the prevention of the formation and/or stabilization of thrombi during and/or after a medical procedure performed on a human or animal subject comprising contacting blood of said human or animal subject with artificial surfaces, wherein said inhibitor of FXII/FXIla is administered before and/or during and/or after said medical procedure.

Compounds for the prevention and treatment of cardiovascular diseases

The present disclosure relates to compounds, which are useful for regulating the expression of apolipoprotein A-I (ApoA-I), and their use for treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis.

Process for demineralization of bone matrix with preservation of natural growth factors

A demineralized bone matrix is produced by a process in which a bone body is placed in a first processing solution comprising an acid to demineralize the bone body. The bone body is periodically removed from the first solution at specific time intervals to perform at least one test, such as a compression test, on a mechanical property of the bone body. When the test yields a desired result, the bone body is exposed to a second processing solution that is less acidic than the first, thus minimizing the exposure of the bone body to the harsh acidic conditions of the demineralization phase of the process.

Use of bacterial polysaccharides for biofilm inhibition

A method comprises preventing or inhibiting bacterial adhesion and/or bacterial biofilm development by treating a substrate with a composition of a soluble group II capsular polysaccharide obtained from a bacterial strain.

Method of making a stent

A method of making a stent, including preparing a solution containing a composition, the composition comprising a biodegradable polymer and a vascular intimal hyperplasia inhibitor of a kind, including argatroban, which does not inhibit proliferation of endothelial cells, the weight compositional ratio of the polymer to the vascular intimal hyperplasia inhibitor being within the range of 8:2 to 3:7, the composition dissolved in a solvent selected from the group consisting of a mixture of a lower alkyl ketone and methanol, a mixture of a lower alkyl ester and methanol or a mixture of a lower halogenated hydrocarbon and methanol; coating at least an outer surface of a stent body of a cylindrical configuration having outer and inner surfaces with a diamond-like thin film coated on the surfaces; and after the coating, removing the solvent to complete a first coated layer.

Progesterone-containing compositions and devices

Progesterone-containing compositions and devices that can maintain opening of a body passageway are described. One aspect of the invention provides a therapeutically effective (e.g., relaxative, anti-oxidative, anti-restenotic, anti-angiogenic, anti-neoplastic, anti-cancerous, anti-precancerous and/or anti-thrombotic) composition or formulation containing progesterone and optionally vitamin E and/or conjugated linoleic acid. Another aspect of the invention provides a drug eluting device, such as a drug eluting stent, with at least one coating layer comprising a progesterone composition that can minimize or eliminate inflammation, thrombosis, restenosis, neo-intimal hyperplasia, rupturing of vulnerable plaque, and/or other effects related to device implantation, treatment, or interaction. Other aspects of the invention provide for methods of using such compositions, formulations, and devices.

MULTI-FUNCTION DRESSING STRUCTURE FOR NEGATIVE-PRESSURE THERAPY

Systems, methods, and apparatuses for forming a multi-function core for a dressing are described. The multi-function core includes a contact layer configured to be positioned adjacent to a tissue site, a wicking layer adjacent to the contact layer, an ion exchange layer adjacent to the wicking layer, an absorbing layer adjacent to the ion exchange layer, a blocking layer adjacent to the absorbing layer, and an odor-absorbing layer adjacent to the blocking layer. The contact layer, the wicking layer, the ion exchange layer, the absorbing layer, the blocking layer, and the odor-absorbing layer are coextensive and formed from a plurality of fibers disposed in a fibrous web. Methods of manufacturing the multi-function core are also described. 170-. (canceled)71. A method for providing negative-pressure therapy to a tissue site , the method comprising: placing a sealing member over the tissue interface and sealing the sealing member to tissue surrounding the tissue site to form a sealed space;', 'fluidly coupling a negative-pressure source to the sealed space;', a contact layer configured to be positioned adjacent to the tissue interface;', 'a fluid dispersion layer coupled to the contact layer;', 'an ion exchange layer coupled to the fluid dispersion layer;', 'a liquid retention layer coupled to the ion exchange layer;', 'a liquid blocking layer coupled to the liquid retention layer;', 'an odor removal layer coupled to the liquid blocking layer; and, 'positioning a fluid management apparatus between the tissue interface and the sealing member, the fluid management apparatus comprising, 'operating the negative-pressure source to draw fluid from the sealed space through the fluid management apparatus and generate a negative pressure in the sealed space., 'positioning a tissue interface adjacent to the tissue site;'}72. The method of claim 71 , wherein the fluid dispersion layer claim 71 , the ion exchange layer claim 71 , the liquid retention layer claim 71 , the liquid ...

POLYTETRAFLUOROETHYLENE CO-POLYMER EMULSIONS

The present disclosure is directed to a class of fluorinated copolymers, such as PTFE copolymers, that can be dissolved in low toxicity solvents, such as Class III Solvents, and that enable the creation of stable water-in-solvent emulsions comprising the fluorinated copolymers dissolved in a low toxicity solvents and a hydrophilic agent (e.g., a therapeutic agent) dissolved in an aqueous solvent, such as water or saline. 1. A method of preparing a water in solvent emulsion comprising the steps of:a. Dissolving a tetrafluoroethylene copolymer in a water miscible organic solvent;b. Providing a water phase;c. Dissolving an agent comprising one of a water soluble agent and a hydrophobic agent; andd. Combining the tetrafluoroethylene copolymer with the dissolved agent, such that the emulsion is kinetically stable.2. The method of claim 1 , wherein the agent is a therapeutic agent.3. The method of claim 1 , wherein the agent is an inclusion complex comprising a hydrophobic agent and a hydrophilic complexing agent.4. The method of claim 1 , wherein the agent is a water soluble agent which is dissolved into the water phase.5. A method of coating a substrate comprising a water-in-solvent emulsion claim 1 , the method comprising the steps of:a. Providing a water in solvent emulsion comprising a tetrafluoroethylene copolymer, a solvent phase comprising a water miscible organic solvent, an agent comprising one of a water soluble agent and a hydrophobic agent, a water phase, wherein the emulsion is kinetically stable;b. Applying the water-in-solvent emulsion to the substrate; andc. Removing the solvent and water.6. The method of claim 5 , wherein the agent is an inclusion complex comprising a hydrophobic agent and a hydrophilic complexing agent.7. The method of claim 5 , wherein the water phase is less than about 500 nm by Raman spectroscopy.8. The method of claim 5 , wherein the tetrafluoroethylene copolymer comprises functional groups selected from a group consisting of ...

ABSORBENT ARTICLE HAVING A LOTIONED TOPSHEET

The absorbent article of the invention has a liquid impervious backsheet and a liquid pervious topsheet joined to the backsheet. The topsheet has an inner surface oriented toward the interior of the absorbent article and an outer surface oriented toward the skin and hair of the wearer when the absorbent article is being worn and an absorbent core positioned between the topsheet and the backsheet. At least a portion of the topsheet outer surface comprises an effective amount of a lotion coating which is semi-solid or solid at 20 degrees C., the lotion coating comprising: 1. An absorbent article comprising:A) a liquid impervious backsheet;B) a liquid pervious topsheet joined to said backsheet, said topsheet having an inner surface oriented toward the interior of said absorbent article and an outer surface oriented toward the skin and hair of the wearer when said absorbent article is being worn, wherein at least a portion of said topsheet outer surface comprises an effective amount of a lotion coating having a HLB value below 7; andC) an absorbent core positioned between said topsheet and said backsheet.3. The absorbent article of wherein said article is selected from the group consisting of feminine hygiene garments claim 1 , sanitary napkins claim 1 , pantiliners claim 1 , and interlabial devices.4. The absorbent article of wherein said lotion comprises an emollient containing about 5% or less water and comprises a petroleum based emollient selected from the group consisting of mineral oil claim 1 , petrolatum claim 1 , and mixtures thereof.5. The absorbent article of wherein the lotion comprises an agent capable of immobilizing an emollient claim 1 , said agent capable of immobilizing said emollient comprises a member selected from the group consisting of carnauba wax claim 1 , beeswax claim 1 , candelilla wax claim 1 , paraffin wax claim 1 , ceresin wax claim 1 , esparto wax claim 1 , ouricuri wax claim 1 , rezowax claim 1 , and combinations thereof.6. The ...

Surface-independent, surface-modifying, multifunctional coatings and applications thereof

The present invention provides a surface-independent surface-modifying multifunctional biocoating and methods of application thereof. The method comprises contacting at least a portion of a substrate with an alkaline solution comprising a surface-modifying agent (SMA) such as dopamine so as to modify the substrate surface to include at least one reactive moiety. In another version of the invention, a secondary reactive moiety is applied to the SMA-treated substrate to yield a surface-modified substrate having a specific functionality.

COMPOSITIONS AND METHODS FOR CELL KILLING

A solid buffer including one or more ion exchange materials, wherein said solid buffer has a volumetric buffering capacity greater than about 20 mM H/(L·pH unit) and further wherein, when said material is in an environment capable of transporting H ions, said solid buffer is adapted to cause the death of at least one target cell within or in contact with said environment. A selectively permeable barrier layer may be provided covering the solid buffer. 143-. (canceled)44. A method of generating a change in a cellular process of a target eukaryotic cell , said method comprising contacting the target cell with a solid buffer so as to alter an intracellular pH value in at least a portion of said target cell , thereby generating said change in a cellular process of a target cell , wherein said solid buffer comprises one or more solid ion exchange materials having one or more functional groups selected to dissociate H+ ions , wherein said solid buffer having volumetric buffering capacity greater than about 20 mM H+/(L·pH unit) in an environment capable of transporting H+ ions , said solid buffer comprises a sulfonated polystyrene polymer or a sulfonated tetrafluoroethylene copolymer and is adapted to cause the death of at least one target cell within or in contact with said environment.4568-. (canceled)69. An article of manufacture comprising:(i) a support; and(ii) a solid buffer layer being attached to at least part of a surface of said support, said solid buffer comprises a buffering layer and an ion permeable layer being disposed on an external surface of said buffering layer,wherein said solid buffer comprises one or more solid ion exchange materials having one or more functional groups selected to dissociate H+ ions, wherein said solid buffer having volumetric buffering capacity greater than about 20 mM H+/(L·pH unit) in an environment capable of transporting H+ ions, said solid buffer comprises a sulfonated polystyrene polymer or a sulfonated tetrafluoroethylene ...

BIOSWELLABLE SUTURES

Bioswellable sutures are provided in the form of absorbable, compliant monofilaments of an amphiphilic copolyester, an absorbable multifilament braid, a non-absorbable monofilament with swellable outer layer, a non-absorbable multifilament braid with an absorbable monofilament core of an amphiphilic copolymer, and a non-absorbable, multifilament braid molecularly integrated with an outer sheath that is highly hydrophilic. 1. A bioswellable suture comprising a compliant monofilament comprising an absorbable polyether-ester , the monofilament having a tensile modulus of less than about 400 Kpsi and exhibiting an at least 20 percent increase in cross-sectional area and an at least 5 percent decrease in tensile modulus when placed in a biological environment.2. A bioswellable suture as in wherein the polyether-ester comprises a polyether glycol end-grafted with at least one cyclic monomer selected from the group consisting of l-lactide claim 1 , glycolide claim 1 , p-dioxanone claim 1 , trimethylene carbonate claim 1 , ε-caprolactone claim 1 , 1 claim 1 ,5-dioxepan-2-one and a morpholinedione.3. A bioswellable suture as in wherein the polyether glycol is selected from the group consisting of polyethylene glycol claim 2 , polypropylene glycol claim 2 , and block copolymers of ethylene glycol and propylene glycol.4. A bioswellable suture as in wherein the polyether glycol is a solid polyethylene glycol having a molecular weight of greater than about 8 kDa.5. A bioswellable suture as in wherein the polyethylene glycol comprises at least about 10 weight percent of the total polyether-ester mass.6. A bioswellable suture as in further comprising a surface coating on the monofilament claim 5 , wherein the surface coating comprises at least about 0.01 weight percent of total mass of the suture.7. A bioswellable suture as in wherein the surface coating comprises an ε-caprolactone copolymer.8. A bioswellable suture as in wherein the surface coating contains at least one bioactive ...

BLOCK COPOLYMERS OF ACRYLATES AND METHACRYLATES WITH FLUOROALKENES

A block copolymer comprising a fluorinated block and a non-fluorinated block and method of making the block copolymer are provided. Also provided herein are a coating on an implantable device comprising the block copolymer and method of using the implantable device. 140-. (canceled)421. The coating composition of claim , wherein the non-fluorinated block comprises one or more fluorinated pendant groups.432. The coating composition of claim , wherein the fluorinated pendant group is —CF.441. The coating composition of claim , wherein the bioactive agent is tacrolimus , dexamethasone , rapamycin , everolimus , 40-O-(3-hydroxy)propyl-rapamycin , 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin , or 40-O-tetrazole-rapamycin.451. An implantable device comprising the coating composition of claim .465. The implantable device of claim , wherein the non-fluorinated block comprises one or more fluorinated pendant groups.476. The implantable device of claim , wherein the fluorinated pendant group is —CF.485. The implantable device of claim , wherein the bioactive agent is tacrolimus , dexamethasone , rapamycin , everolimus , 40-O-(3-hydroxy)propyl-rapamycin , 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin , or 40-O-tetrazole-rapamycin.495. The implantable device of claim , wherein the implantable device is a drug-eluting stent.509. The implantable device of claim , wherein the stent is a self-expandable stent , balloon-expandable stent , or stent-graft.515. The implantable device of claim , wherein the implantable device is a graft , artificial heart valve , cerebrospinal fluid shunt , pacemaker electrode , or endocardial lead.5211. The implantable device of claim , wherein the graft is an aortic graft.5413. The coating composition of claim , wherein the bioactive agent is tacrolimus , dexamethasone , rapamycin , everolimus , 40-O-(3-hydroxy)propyl-rapamycin , 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin , or 40-O-tetrazole-rapamycin.5513. An implantable device comprising the coating ...

IMPLANTS WITH ABSORBALBLE AND NON-ABSORBABLE FEATURES FOR THE TREATMENT OF FEMALE PELVIC CONDITIONS

Described are methods, devices, and systems related to implants for the treatment of a female pelvic condition. The implants include absorbable and non-absorbable materials and can be introduced into the pelvic area transvaginally. Meshes of the invention provide benefits relating to improved tissue integration into the mesh, reduced infection likelihood, improved patient comfort following implantation, or combinations of thereof. 119-. (canceled)20. An implant configured for transvaginal insertion into a female patient to treat a pelvic disorder or disease , the mesh comprising a non-absorbable mesh layer , and an absorbable material , wherein absorbable material comprises a bioactive agent selected from the group consisting of an antibiotic , antimicrobial , an inhibitor of epithelial cell activation and/or migration , and a compound that enhances wound regeneration , and the absorbable material is in the form of a coating on the non-absorbable mesh , an absorbable filament associated with the non-absorbable mesh , or a second layer associated with the non-absorbable mesh layer.21. The implant of wherein the bioactive agent is estrogen or estradiol22. The implant of further comprising another bioactive agent is selected from the group consisting of an antibiotic claim 21 , an antimicrobial claim 21 , an inhibitor of epithelial cell activation and/or migration claim 21 , epidermal grown factor (EGF) claim 21 , transforming growth factor a or β (TGF-α or β) claim 21 , vascular endothelial growth factor claim 21 , platelet derived growth factor claim 21 , and fibroblast growth factor.23. The implant of wherein the bioactive agent diffuses from or is released from the absorbable material upon its degradation.24. The implant of wherein the absorbable material comprises a hydroxyalkanoate polymer.25. The implant of wherein the absorbable material comprises polyhydroxybutyrate.26. The implant of comprising a second absorbable material.27. The implant of wherein the ...

SURFACE-MODIFIED METAL AND METHOD FOR MODIFYING METAL SURFACE

Provided are surface-modified metals such as metal medical devices, e.g. guide wires, syringe needles, and metal tubes in medical devices or equipment, and methods for modifying a metal surface, wherein a lubricant layer is firmly bonded to the metal surface to impart lubricity to the metal surface and further to improve the durability of the lubricant layer on the metal surface, thereby suppressing deterioration of the sliding properties. Included is a surface-modified metal at least partially having a treated surface, the treated surface being obtained by treating a surface of a metal with a silane coupling agent, followed by adsorbing a hydrogen abstraction type photopolymerization initiator onto the surface and then polymerizing a monomer in the presence of an alkali metal salt. 1. A surface-modified metal , at least partially having a treated surface , the treated surface being obtained by treating a surface of a metal with a silane coupling agent , followed by adsorbing a hydrogen abstraction type photopolymerization initiator onto the surface and then polymerizing a monomer in the presence of an alkali metal salt.2. The surface-modified metal according to claim 1 ,wherein the treated surface is obtained by, after adsorbing the hydrogen abstraction type photopolymerization initiator onto the surface and then polymerizing the monomer in the presence of the alkali metal salt, further performing the following step at least once: polymerizing a monomer in the presence of a hydrogen abstraction type photopolymerization initiator and an alkali metal salt; or adsorbing a hydrogen abstraction type photopolymerization initiator onto the surface and then polymerizing a monomer in the presence of an alkali metal salt.3. A surface-modified metal claim 1 , at least partially having a treated surface claim 1 , the treated surface being obtained by treating a surface of a metal with a silane coupling agent claim 1 , followed by polymerizing a monomer in the presence of a ...

CATHETER INCLUDING LEAK RESISTANT PROXIMAL SHAFT

A catheter may include a hypotube defining an inner circumferential surface, an outer circumferential surface, and an end. The hypotube may include a metal or alloy. The catheter also may include an inner liner attached to the inner circumferential surface of the hypotube and extending beyond the end of the hypotube, and the inner liner may include a fluoropolymer. The catheter further may include a hub and a single bonding layer attached to the outer circumferential surface of the hypotube and bonded to the hub. The single bonding layer may include a polyamide, a polyether-co-polyamide, or polyurethane and is the only layer between the outer circumferential surface of the hypotube and the hub. 1. A catheter comprising:a hypotube defining an inner circumferential surface, an outer circumferential surface, and an end, wherein the hypotube comprises a metal or alloy;an inner liner attached to the inner circumferential surface of the hypotube and extending beyond the end of the hypotube, wherein the inner liner comprises a fluoropolymer;a hub; anda single bonding layer attached to the outer circumferential surface of the hypotube and bonded to the hub, wherein the single bonding layer comprises a polyamide or a polyether-co-polyamide, and wherein the single bonding layer is the only layer between the outer circumferential surface of the hypotube and the hub.2. The catheter of claim 1 , wherein the single bonding layer consists essentially of the polyamide or the polyether-co-polyamide.3. The catheter of claim 1 , wherein the single bonding layer consists essentially of polyether-co-polyamide.4. The catheter of claim 1 , wherein the single bonding layer consists essentially of polyurethane.5. The catheter of claim 1 , wherein the single bonding layer consists essentially of Acrylate-butadiene-styrene copolymer.6. The catheter of claim 1 , wherein the hub comprises polypropylene.7. The catheter of claim 1 , wherein the hub is overmolded or adhesively bonded to the single ...

BIOLOGICAL SCAFFOLD AND METHOD FOR FABRICATING THE SAME

A biological scaffold in the present invention comprises a main body, a biological material layer, and an optional tissue adhesive layer. The main body at least has a non-constituted collagen matrix. The biological material layer is coated at least on a surface of the main body, and the tissue adhesive layer is disposed at least on another surface of the main body. When the biological scaffold is adhered to a tissue through the tissue adhesive layer, a plurality of cells move from the tissue to either the adhesive layer or the biological material layer for tissue repairing or regeneration. 1. A biological scaffold , comprising:a main body including a de-antigenic, non-reconstituted collagen matrix, wherein the non-reconstituted collagen matrix contains a plurality of bundled collagen fibrils that are interwoven and overlapped and a plurality of pores formed by the bundled collagen fibrils; anda biological material coating a first outer surface and inside the plurality of pores of the main body, optionally, the biological material substantially coats the entire surface and inside of the main body.2. The biological scaffold of claim 1 , wherein the biological material is selected from the group consisting of a cell attachment material claim 1 , a tissue repair material claim 1 , a cell induction material claim 1 , a growth factor material claim 1 , an antibacterial material claim 1 , and a combination thereof.3. The biological scaffold of claim 2 , wherein:the antibacterial material is an antibiotic, an antimicrobial protein, an antimicrobial peptide, or a combination thereof;the cell attachment material is a saccharide, a peptide, a protein, a phospholipid, or a combination thereof, optionally, the saccharide material is a glycosaminoglycan material;the growth factor material is epidermal growth factor (EGF), fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), connective tissue growth factor (CTGF), platelet-derived growth factor (PDGF), ...

Rollable bone implant for enclosing bone material

A bone implant for enclosing bone material is provided. The bone implant comprises a covering, which can be a biodegradable mesh. The covering is configured to be rolled into a diameter to at least partially enclose the bone material within the covering. In some embodiments, the covering includes a body portion and a closure portion adjacent to the body portion. The closure portion is configured to hold the covering in a rolled configuration to a predetermined diameter to at least partially enclose the bone material. A kit and a method of using the bone implant are also provided.

ABSORBENT ARTICLE

The purpose of the present invention is to provide an absorbent article in which a top sheet () does not have the conventional concavo-convex shape, and the top sheet () feels dry and does not feel sticky even after absorbing menstrual blood having a high viscosity. This absorbent article has a liquid-permeable top sheet (), a liquid-impermeable back sheet (), and an absorbent () disposed between the liquid-permeable top sheet () and the liquid-impermeable back sheet (), wherein the liquid-permeable top sheet () has a grammage of 5 to 30 g/mand a thickness of 0.10 to 0.30 mm in a region that comes into contact with an excretory opening, the liquid-permeable top sheet () contains a blood modifier () in the skin abutting surface () of the region that comes into contact with an excretory opening, and the blood modifier () is a polyoxypropylene-glycol-based compound. 1. An absorbent article comprising a liquid-permeable top sheet , a liquid-impermeable back sheet and an absorbent body between the liquid-permeable top sheet and the liquid-impermeable back sheet ,{'sup': '2', 'wherein the liquid-permeable top sheet has a thickness of 0.10 to 0.30 mm and a basis weight of 5 to 30 g/min the excretory opening contact region,'}the liquid-permeable top sheet includes a blood modifying agent on the skin contact surface of the excretory opening contact region, andthe blood modifying agent is a polyoxypropylene glycol-based compound.2. The absorbent article according to claim 1 , wherein the liquid-permeable top sheet is a spunbond nonwoven fabric or an SMS nonwoven fabric.3. The absorbent article according to claim 1 , wherein the liquid-permeable top sheet is a porous film.4. The absorbent article according to claim 1 , wherein the blood modifying agent is selected from the group consisting of the following (A) to (E) claim 1 , and any combination thereof:(A) polyoxypropylene glycol,(B) a mono or diether of (B1) polyoxypropylene glycol and (B2) a compound having a hydrocarbon ...

ABSORBENT ARTICLE

The objective of the present disclosure is to provide an absorbent article having a dry top sheet without any feeling of stickiness in the top sheet, even after high viscosity menstrual blood has been absorbed. The absorbent article of the present disclosure has the following structure. The absorbent article () has a liquid-permeable top sheet (), a liquid-impermeable back sheet, and an absorbent body (). The absorbent article () is characterized by: having an excretory orifice contact region (), first embossed portions (), an external peripheral region (), and second embossed portions (); the first embossed portions () and second embossed portions () being formed by embossing a layer comprising the top sheet () and the absorbent body (); and the top sheet () inside the excretory orifice contact region () and the second embossed portions () respectively comprising a prescribed blood lubricating agent.

Titanium Dioxide Coatings for Medical Devices Made by Atomic Layer Deposition

Implantable medical devices coated with multiple atomic layers of amorphous titanium dioxide applied by atomic layer deposition have improved mammalian cell adhesion and inhibition of bacterial growth. Thickness of the coating can be used to tune resorption of bioresorbable vascular scaffolds for treatments of cardiovascular disease.

COATED MEDICAL DEVICE PRODUCT AND PROCESS

Medical device products have a coating with NAMSA Class VI certification and properties corresponding to the prior art coatings within U.S. Pat. No. 10,604,660. Medical device processes use the medical device product having a coating with NAMSA Class VI certification and properties corresponding to the prior art coatings within U.S. Pat. No. 10,604,660. 1. A medical device product having a coating with NAMSA Class VI certification and properties corresponding to the prior art coatings within U.S. Pat. No. 10 ,604 ,660.2. The medical device product of claim 1 , wherein the coating is on a fitting.3. The medical device product of claim 1 , wherein the coating is on tubing.4. The medical device product of claim 1 , wherein the coating is on a valve.5. The medical device product of claim 1 , wherein the coating is on a filter.6. The medical device product of claim 1 , wherein the coating is on a frit.7. The medical device product of claim 1 , wherein the coating is on a probe.8. The medical device product of claim 1 , wherein the coating is on metal.9. The medical device product of claim 1 , wherein the coating is on glass.10. The medical device product of claim 1 , wherein the medical device is a therapeutic device.11. The medical device product of claim 1 , wherein the medical device is a wound care device.12. The medical device product of claim 1 , wherein the medical device is a catheter.13. The medical device product of claim 1 , wherein the medical device is an interrogator.14. The medical device product of claim 1 , wherein the medical device is positioned within a human.15. The medical device product of claim 1 , wherein the medical device is a surgical instrument.16. The medical device product of claim 1 , wherein the medical device is a perfusion device.17. The medical device product of claim 1 , wherein the medical device is a gastric bypass device.18. The medical device product of claim 1 , wherein the medical device is a drug delivery device.19. The medical ...

COMPOSITION INCLUDING BIOACTIVE BONE GRAFTING MATERIALS AND A METALLIC SURFACE COATING, METHOD OF MAKING AND USING THE COMPOSITION

Compositions including bioactive glass ceramic material surface-coated with a metallic material and methods of making and using the metallic material-coated compositions. 1. A bone grafting composition comprising a bioactive glass ceramic material at least partially surface-coated with a metallic material having an atomic mass greater than 45 and less than 205.2. The bone grafting composition of claim 1 , wherein the metallic material is selected from the group consisting of gold claim 1 , silver claim 1 , platinum claim 1 , copper claim 1 , palladium claim 1 , iridium claim 1 , strontium claim 1 , cerium claim 1 , an isotope claim 1 , an alloy or a combination thereof.3. The bone grafting composition of claim 1 , wherein the bioactive glass ceramic material is in a form of a particle claim 1 , a sheet claim 1 , a fiber claim 1 , a strip claim 1 , a block claim 1 , a wedge claim 1 , a mesh claim 1 , or any combination of these forms.4. The composition of claim 1 , wherein the metallic material is physically or chemically bound to the bioactive glass ceramic material.5. The composition of claim 1 , wherein the bioactive glass ceramic material comprises at least one of silica claim 1 , boron claim 1 , and calcium phosphate.6. The composition of claim 1 , wherein the weight ratio of the metallic material is less than about 20% relative to the weight of the synthetic bone grafting composition.7. The composition of claim 1 , wherein the weight ratio of the metallic material is about 0.0001-20 wt % relative to the weight of the synthetic bone grafting composition.8. The composition of claim 1 , wherein the weight ratio of the metallic material is 0.0001-10 wt % relative to the weight of the synthetic bone grafting composition.9. The composition of claim 1 , wherein the weight ratio of the metallic material is 0.0001-5 wt % relative to the weight of the synthetic bone grafting composition.10. The composition of claim 1 , wherein the weight ratio of the metallic material is ...

CORROSION-RESISTANT MAGNETIC ARTICLE

A magnetic article with a corrosion resistant barrier formed from a poly (tetrafluoro-p-xylene) conformal coating or from a parylene conformal coating having a melting point of at least about 430° C. and a moisture vapor transmission less than about 0.5 g-mm/m/day at 90% RH and 37° C., the conformal coating being covered with a polysulfone thermoplastic overlayer. 1. A magnetic article comprising an NdFeB magnet having thereon a substantially continuous corrosion resistant barrier comprising a fluorinated parylene conformal coating covered with a polysulfone thermoplastic overlayer.2. A magnetic article according to wherein the magnet has a Maximum Energy Product BHof at least 28 Mega Gauss Oersteds claim 1 , an Intrinsic Coercive Force Hof at least 10 kiloOersteads and a Curie Temperature Tof at least 300° C.3. A magnetic article according to wherein the magnet has a Maximum Energy Product BHof at least 32 Mega Gauss Oersteds claim 1 , an Intrinsic Coercive Force H{'sub': 'c', 'of at least 35 kiloOersteads and a Curie Temperature Tof at least 310° C.'}4. A magnetic article according to wherein the magnet comprises a bar claim 1 , rod claim 1 , ring claim 1 , partial ring or plate.5. A magnetic article according to wherein the fluorinated parylene has fluoroaliphatic groups.6. A magnetic article according to wherein the conformal coating comprises poly(tetrafluoro-p-xylene).7. A magnetic article according to wherein the fluorinated parylene has fluoroaromatic groups.8. A magnetic article according to wherein the conformal coating comprises parylene VT-4.9. A magnetic article according to wherein the conformal coating has a thickness of 2 to 100 μm.10. A magnetic article according to wherein the overlayer comprises polyethersulfone.11. A magnetic article according to wherein the overlayer comprises sulfonated polyethersulfone or polyphenylsulfone.12. A magnetic article according to wherein the overlayer has an average thickness of 0.5 to 10 mm.13. A magnetic article ...

PLEURAL DRAINAGE SYSTEM AND METHOD OF USE

A pleural drainage system having an inflatable membrane and a method of using the system are disclosed. The pleural drainage system includes a pleural drainage catheter system. The pleural drainage catheter system includes an inflatable membrane and a drainage catheter integrally coupled to the inflation membrane, the drainage catheter defining a drainage lumen through which fluid is drawn from the pleural cavity, and an inflation lumen coupled for flow of inflation fluid to and from an interior of the inflatable membrane. The pleural drainage system further includes a suction system coupled to the drainage catheter and a fluid collector coupled to receive fluid from the drainage catheter. The pleural drainage system further includes an inflation system connected to deliver inflation fluid to the interior of the inflatable membrane. The pleural drainage system may be used to monitor an associated airleak in the pleural cavity of a patient. 1. A pleural drainage catheter system configured to extend into a pleural cavity of a patient and to drain fluid from the pleural cavity of the patient , said pleural drainage catheter system comprising:an inflatable membrane comprising two opposed layers formed from a bio-compatible material, the inflatable membrane having a deflated state in which the layers are positioned substantially adjacent one another and an inflated state in which at least portions of the respective layers are spaced from one another, an external surface of the inflatable membrane defining one or more passages that facilitate the movement of fluid along the external surface for removal from the pleural cavity when the inflatable membrane is in the inflated state; anda drainage catheter integrally coupled to the inflatable membrane, the drainage catheter defining a drainage lumen, a plurality of drainage openings through which fluid is drawn into the drainage lumen from the pleural cavity, and an inflation lumen coupled for flow of inflation fluid to and ...

MEDICAL DEVICE HAVING A SURFACE COMPRISING GALLIUM OXIDE

A medical device intended for contact with living tissue comprises a substrate having a surface, which surface comprises a layer comprising gallium oxide. A layer comprising a gallium oxide has been shown to inhibit biofilm formation on the surface of the medical device, which may reduce the risk for infection e.g. around a dental implant. A method of producing the medical device comprises: a) providing a substrate having a surface; and applying a gallium compound onto said surface to form a layer, preferably using a thin film deposition technique. 1. A medical device intended for contact with living tissue , comprising a substrate having a surface layer comprising GaO.2. The medical device according to claim 1 , wherein said living tissue is soft tissue.3. The medical device according to claim 1 , wherein said layer has a thickness in the range of from 10 nm to 1.5 μm.4. The medical device according to claim 1 , wherein said layer has a gallium content of at least 5 at %.5. The medical device according to claim 1 , wherein said layer has a gallium content of up to 40 at %.6. The medical device according to claim 1 , wherein said layer is a homogeneous layer.7. The medical device according to claim 1 , wherein said layer is a non-porous layer.8. The medical device according to claim 1 , wherein said substrate comprises a metallic material.9. The medical device according to claim 1 , wherein said substrate comprises a ceramic material.10. The medical device according to claim 1 , wherein said substrate comprises a polymeric material.11. The medical device according to claim 1 , wherein said substrate comprises a composite material.12. The medical device according to claim 1 , which is an implant intended for long-term contact with living tissue.13. The medical device according to claim 1 , which is intended for prolonged contact with living tissue.14. The medical device according to claim 1 , which is intended for short-term contact with living tissue.15. The medical ...

Multi-function dressing structure for negative-pressure therapy

Systems, methods, and apparatuses for forming a multi-function core for a dressing are described. The multi-function core includes a contact layer configured to be positioned adjacent to a tissue site, a wicking layer adjacent to the contact layer, an ion exchange layer adjacent to the wicking layer, an absorbing layer adjacent to the ion exchange layer, a blocking layer adjacent to the absorbing layer, and an odor-absorbing layer adjacent to the blocking layer. The contact layer, the wicking layer, the ion exchange layer, the absorbing layer, the blocking layer, and the odor-absorbing layer are coextensive and formed from a plurality of fibers disposed in a fibrous web. Methods of manufacturing the multi-function core are also described.

ION EXCHANGE ABSORBENT SYSTEMS, APPARATUSES, AND METHODS

Systems, methods, and apparatuses for increasing liquid absorption are described. Some embodiments may include a dressing having an absorbent layer containing super-absorbent material as well as ionic-exchange media (IEM). In some embodiments, the absorbent layer may include absorbent fibers. The absorbent fibers may each include a super-absorbent core surrounded by a water-permeable layer onto which ionic-exchange media (IEM) may be grafted. As liquid comes into contact with the IEM, its ionic nature may be reduced, therefore protecting the absorbent qualities of the super-absorbent material. 1. A fiber , comprising:an absorbent core;a filter layer disposed around the absorbent core; andan ion-exchange media disposed in the filter layer and adapted to reduce an ionic concentration of a fluid.2. The fiber of claim 1 , wherein the filter layer is coated on the absorbent core.3. The fiber of claim 1 , wherein the filter layer encloses the absorbent core.4. The fiber of claim 1 , wherein the ion-exchange media comprises a cation-exchange media.5. The fiber of claim 1 , wherein the ion-exchange media comprises an anion-exchange media.6. The fiber of claim 1 , wherein the ion-exchange media comprises:cation-exchange media;anion-exchange media; andthe cation-exchange media and the anion-exchange media are dispersed throughout the filter layer.7. The fiber of claim 1 , wherein the ion-exchange media comprises porous beads formed from cross-linked polymers doped or grafted with acidic polymers.8. The fiber of claim 7 , wherein the cross-linked polymers comprise polystyrene and the acidic polymers comprise poly(2-acrylamido-2-methyl-1-propanesulfonic acid) and poly(acrylamido-N-propyltrimethylammonium chloride).9. The fiber of claim 1 , wherein the ion-exchange media comprises an alkaline polymer.10. The fiber of claim 9 , wherein the alkaline polymer is poly(acrylamido-N-propyltrimethylammonium chloride).11. The fiber of claim 1 , wherein the ion-exchange media comprises a ...

COPOLYMER, ANTITHROMBOTIC COATING AGENT USING SAME AND MEDICAL DEVICE

A biocompatible material, which has excellent film formation properties and resistance to water dissolution, and is easily applied on various bases as a coating, while having excellent antithrombotic properties, and to provide an antithrombotic coating agent and an antithrombotic coating film produced by using the biocompatible material, and a medical device provided with the antithrombotic coating film. A copolymer, containing at least one repeating unit (A) represented by formula (1) (wherein, n represents an integer of 2 to 10 and Rrepresents a methyl group or an ethyl group), and at least one repeating unit (B) represented by formula (2) (wherein Rrepresents an aliphatic hydrocarbon group); an antithrombotic coating agent containing the copolymer and an organic solvent; an antithrombotic coating film formed of the copolymer; and a medical device provided with the coating film. 2: The copolymer according to claim 1 , wherein the composition ratio (molar ratio) of the repeating unit (A) to the repeating unit (B) is 90/10 to 1/99.3: The copolymer according to claim 1 , wherein Ris a linear or branched alkyl group or alkenyl group having 2 to 10 carbon atoms or a monocyclic or polycyclic alkyl group or alkenyl group having 5 to 15 carbon atoms.4: The copolymer according to claim 1 , wherein Ris a linear or branched alkyl group or alkenyl group having 2 to 10 carbon atoms.5: A biocompatible material claim 1 , comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'the copolymer according to .'}6: An antithrombotic coating agent claim 1 , comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'the copolymer according to and'}an organic solvent.7: The antithrombotic coating agent according to claim 6 , wherein the organic solvent is at least one selected from the group consisting of an aromatic hydrocarbon claim 6 , an aliphatic hydrocarbon claim 6 , a halogenated hydrocarbon claim 6 , an ether claim 6 , an alcohol claim 6 , a ketone claim 6 , and an ester. ...

ANALOGS OF PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP) AND METHODS FOR THEIR USE

This invention relates to novel analogs of pituitary adenylate cyclase-activating polypeptide (PACAP), which are agonists for the PACAP/vasoactive intestinal peptide (VIP) receptors: PAC1, VPAC1 and VPAC2 receptors. These PACAP analogs can be used as prophylactic/therapeutic agents for a wide range of medical disorders, including (but not limited to) cancer and autoimmune disease. These PACAP analogs can be coupled to suitable radionuclides and used in the localization, diagnosis and treatment of disseminated cancers and metastatic tumors, or coupled to small molecule therapeutics and used as vectors for targeted drug delivery. This invention also provides pharmaceutical compositions of one or more PACAP-like compounds of the invention either alone or in combination with one or more other prophylactic/therapeutic agents. 1. An isolated compound having formula (I) , or a pharmaceutically acceptable salt thereof:{'br': None, 'sup': 1', '1', '2', '3', '4', '5', '6', '7', '8', '9', '10', '11', '12', '13', '14', '15-', '16', '17', '18', '19', '20', '21', '22', '23', '24', '25', '26', '27', '28', '30', '31', '32', '33', '34', '35', '36', '37', '38', '2, 'R-A-A-A-A-A-A-A-A-A-A-A-A-A-A-AA-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-R,'}wherein:{'sup': '1', 'smallcaps': D', 'D', 'D', 'D, 'Ais His, -His, Tyr, -Tyr, Trp, -Trp, Pal, or -Pal;'}{'sup': '2', 'smallcaps': D', 'D', 'D', 'D', 'D, 'Ais Ser, -Ser, hSer, N-Me-Ser, Thr, -Thr, Ala, -Ala, Ile, -Ile, Pro, -Pro, Abu, Aib, Acb, Ach, Acpe, or Acpr;'}{'sup': '3', 'Ais Pip;'}{'sup': '4', 'smallcaps': 'D', 'Ais Gly, Ala, -Ala, β-Ala, Gaba, Abu, Aib, Acb, Ach, Acpe, or Acpr;'}{'sup': '5', 'Ais Ile, Leu, Nle, Val, Nva, Aib, Acb, Ach, Acpe, or Acpr;'}{'sup': '6', 'Ais Phe, Tyr, Trp, Cha, Bip, or Nal;'}{'sup': '7', 'Ais Thr, Ser, hSer, or Val;'}{'sup': '8', 'Ais Asp, Asn, or Glu;'}{'sup': '9', 'Ais Ser, hSer, Thr, Asn, Asp, Ala, Abu, Aib, Acb, Ach, Acpe, or Acpr;'}{'sup': '10', 'Ais Tyr, Phe, Cha, Nal, or Trp;'}{'sup': '11', 'Ais Ser, ...

Growth-inhibited hydroxyapatite, process for its preparation and use

A growth-inhibited hydroxyapatite is contained in agglomerates of prestructured collagen templates, wherein the prestructured collagen templates are denatured or broken up so that fibrillogenesis of the prestructured collagen templates is inhibited. Epitactic hydroxyapatite crystallites with a crystallite size below a critical nucleus radius are formed on the prestructured collagen templates.

COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES

The present disclosure relates to compounds, which are useful for regulating the expression of apolipoprotein A-I (ApoA-I), and their use for treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis. 175-. (canceled)77. The method according to claim 76 , wherein Ris amino.78. The method according to claim 77 , wherein the compound of Formula II is 2-(4-(bis(2-hydroxyethyl)amino)phenyl)-5 claim 77 ,7-dimethoxyquinazolin-4(3H)-one or a pharmaceutically acceptable salt thereof.79. The method according to claim 76 , wherein Ris selected from hydroxyl and alkoxy.80. The method according to claim 79 , wherein the compound of Formula II is selected from:N-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy)ethyl)methanesulfonamide;2-(4-hydroxy-3-methylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one;2-(4-(2-hydroxyethoxy)-3-methylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one;2-(3,5-dimethyl-4-(2-morpholinoethoxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one; andpharmaceutically acceptable salts thereof.81. The method according to claim 79 , wherein Rand Rare each independently alkyl;{'sub': '2', 'Ris hydrogen; and'}{'sub': '7', 'Ris selected from hydroxyl and alkoxy substituted with a hydroxyl.'}82. The method according to claim 81 , wherein the compound of Formula II is 2-(4-(2-hydroxyethoxy)-3 claim 81 ,5-dimethylphenyl)-5 claim 81 ,7-dimethoxyquinazolin-4(3H)-one or a pharmaceutically acceptable salt thereof.84. The method according to claim 83 , wherein the compound of Formula II is selected from:2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy)ethyl cyclohexylcarbamate;N-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy)ethyl)acetamide;N-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy)ethyl)isobutyramide;1-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6- ...

COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES

The present disclosure relates to compounds, which are useful for regulating the expression of apolipoprotein A-I (ApoA-I), and their use for treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis. 2. The method according to claim 1 , wherein Zis a double bond;{'sub': 2', '3, 'Zand Zare each a single bond;'}{'sub': '11', 'X is selected from N and CR;'}{'sub': 10', 'p, 'for W-(R), W is N and p is 1; and'}{'sub': '2', 'Y is selected from CO, SO, SO, and CS.'}3. The method according to claim 1 , wherein Zis a double bond;{'sub': '11', 'X is NR;'}{'sub': 10', 'p, 'for W-(R), W is N and p is 0; and'}{'sub': '2', 'Y is selected from CO, SO, SO, and CS.'}4. The method according to claim 1 , wherein Zand Zare each a double bond;{'sub': '11', 'X is selected from N and CR;'}{'sub': 10', 'p, 'for W-(R), W is N, and p is 0; and'}{'sub': 12', '12, 'Y is selected from CR, COR, and SO.'}5. The method according to claim 1 , wherein Rand Rare each independently an alkoxy.6. The method according to claim 5 , wherein Rand Rare each independently selected from alkyl and hydrogen; and{'sub': '7', 'Ris selected from amino, hydroxyl, and alkoxy.'}7. The method according to claim 6 , wherein X is CR;{'sub': 10', 'p', '10, 'for W-(R), W is N and Ris hydrogen; and Y is CO.'}8. The method according to claim 6 , wherein X is N;{'sub': 10', 'p', '10, 'for W-(R), W is N and Ris hydrogen; and Y is CO.'}9. The method according to claim 1 , wherein Rand Rare each hydrogen.10. The method according to claim 1 , wherein at least one of R claim 1 , R claim 1 , and Ris not hydrogen.11. The method according to claim 10 , wherein Rand Rare each independently selected from alkyl and hydrogen; and{'sub': '7', 'Ris selected from amino, hydroxyl, and alkoxy.'}12. The method according to claim 11 , wherein X is CR;{'sub': 10', 'p', '10, 'for W-(R), W is N and Ris hydrogen; and Y is CO.'}13. The ...

BIOFILM PREVENTION, DISRUPTION AND TREATMENT WITH BACTERIOPHAGE LYSIN

The present invention provides methods for the prevention, control, disruption and treatment of bacterial biofilms with lysin, particularly lysin having capability to kill Staphlococcal bacteria, including drug resistant , particularly the lysin PlySs2. The invention also provides compositions and methods for use in treatment or modulation of bacterial biofilm(s) and biofilm formation. 1. A method for prevention , disruption or treatment of a gram-positive bacterial biofilm comprising contacting a biofilm with a composition comprising a lysin polypeptide capable of killing Staphylococci , wherein the lysin polypeptide is PlySs2 and the biofilm is effectively prevented , dispersed or treated.2. (canceled)3. The method of wherein the lysin polypeptide comprises an amino acid sequence as set out in (SEQ ID NO: 1) or variants thereof having at least 80% identity to the polypeptide of (SEQ ID NO: 1) and effective to kill the gram-positive bacteria in the biofilm.4. The method of wherein the composition further comprises one or more antibiotic.5. The method of wherein the antibiotic is selected from daptomycin claim 4 , vancomycin claim 4 , and linezolid or a related compound.6. The method of further comprising contacting the biofilm with one or more antibiotic.7. A method of preventing or reducing gram-positive bacterial biofilm formation comprising contacting a medical device claim 1 , catheter claim 1 , or implant with a composition comprising a lysin polypeptide capable of killing Staphylococci wherein the lysin is PlySs2.8. The method of wherein the lysin polypeptide comprises an amino acid sequence as set out in (SEQ ID NO: 1) or variants thereof having at least 80% identity to the polypeptide of (SEQ ID NO: 1) and effective to prevent or reduce the formation of bacterial biofilm or the attachment and growth of bacteria on the medical device claim 7 , catheter claim 7 , or implant.9. The method of wherein the composition further comprises an antibiotic.10. The ...

Chest drainage systems and methods

A chest drainage system including a collection device configured to receive fluid from the pleural cavity of a patient. A sensor is included to detect a pressure differential in the fluid. A display is configured to display a trend in occurrences of changes in pressure of the fluid over time in predetermined time increments based on a number of detections of pressure differentials that exceed a predetermined pressure differential during each of the predetermined time increments. The trend is correlative to the percentage of time that the patient is deemed to have an air leak in the pleural cavity in the predetermined time increments. The trend is derived from a ratio of the quantity of respiratory cycles of the patient for which the predetermined pressure differential is detected (QRC leak ) in the predetermined time increments to the total quantity of respiratory cycles of the patient in respective predetermined time increments (QRC total ).

Calibration and detection of silicone oil in syringe barrels

Medical syringe barrels having the inner surface coated with cured silicone oil are used for calibration and detection of silicone oil in medical syringe barrels. Calibration standards as provided in this invention allow for quick determination how well a lubrication system for lubricating medical syringe barrels with silicone oil is working. 1. A method of calibration and detection of silicone oil in syringe barrels , comprising:(a) providing a syringe barrel which has the inner surface coated with a silicone oil;(b) obtaining an image with an imaging system of the inner surface of the syringe barrel coated with the silicone oil, wherein the imaging system is capable of detecting silicone oil;(c) determining with a computer image analysis program executed by a computer a distribution pattern of the silicone oil at the inner surface from the obtained image;(d) determining by the computer image analysis program executed by the computer a comparison between (i) the distribution pattern of the silicone oil at the inner surface of the syringe barrel, with (ii) a calibration distribution pattern of an inner surface of a calibration syringe barrel coated with a cured silicone oil, wherein the silicone oil in the cured silicone oil is the same silicone oil as in the syringe barrel, wherein the calibration distribution pattern of the cured silicone oil is obtained from a calibration image obtained with the imaging system of the inner surface of calibration syringe barrel; and(e) outputting the comparison by the computer image analysis program executed by the computer.2. The method as set forth in claim 1 , wherein the cured silicone oil is chemically doped with a fluorescent material or a fluorescent tag that can be dissolved in silicone oil.3. The method as set forth in claim 1 , wherein the cured silicone oil is chemically or physically doped with a hydrophobic quantum dot.4. The method as set forth in claim 1 , wherein the cured silicone oil is a curable ...

SOLUBLE BACTERIAL AND FUNGAL PROTEINS AND METHODS AND USES THEREOF IN INHIBITING AND DISPERSING BIOFILM

The present disclosure relates to methods of treating or preventing a biofilm-related infection and methods of preventing and treating biofilm formation on indwelling medical devices, implants, and non-medical surfaces comprising administering at least one soluble microbial protein that is encoded by an exopolysaccharide biosynthetic operon or functional gene cluster, wherein the protein comprises a glycosyl hydrolase domain. The present disclosure further provides particular soluble glycosyl hydrolases and compositions thereof. 1. A method of treating or preventing a biofilm-related infection comprising administering at least one , at least two of , at least three of , at least four of , at least five of , or all of: (i) a soluble protein comprising a SphGH domain , (ii) a soluble protein comprising a PelA GH domain , (iii) a soluble protein comprising a BpsB GH domain , (iv) a soluble protein comprising a PgaB GH domain , (v) a soluble protein comprising a PslG glycosyl hydrolase (GH) domain and (vi) a soluble protein comprising an Ega3 GH domain , or orthologs thereof , to an animal or plant in need thereof.2. The method of claim 1 , wherein(a) the soluble protein comprising a Sph3 GH domain comprises amino acids 52 to 298 of the Sph3 sequence deposited into GenBank under accession no. EAL92786.1 or a glycosyl hydrolase variant thereof;(b) the soluble protein comprising a Sph3 GH domain ortholog comprises amino acids 54 to 304 of the Sph3 sequence deposited into Genbank under accession no. EAW09379.1 or a glycosyl hydrolase variant thereof;(c) the soluble protein comprising a Sph3 GH domain ortholog comprises amino acids 43 to 299 of the Sph sequence deposited into Genbank under accession no. EAA63523.1 or a glycosyl hydrolase variant thereof;(d) the soluble protein comprising a PelA GH domain comprises amino acids 47 to 303 of the PelA sequence deposited into GenBank under accession no. AAG06452.1 or amino acids 35-291 of the PelA sequence deposited into GenBank ...

Polyurethane Based Medical Articles

Medical articles formed from a polyurethane-based resin including an ionically-charged modifier provide enhanced properties. The polyurethane-based resin is a reaction product of ingredients comprising: a diisocyanate; a diol chain extender; a polyglycol; and an ionically-charged modifier incorporated into a backbone, as a side chain, or both of the polyurethane-based resin. Embodiments include the ionically-charged modifier is a combination of anionic and cationic modifiers. Embodiments include the ionically-charged modifier is zwitterionic. Medical articles herein either have inherent antimicrobial and/or anti-fouling characteristics or can easily bond ionic active agents to provide desirable material properties, including antimicrobial, anti-fouling, and/or radiopacity. 1. A medical article formed from a polyurethane-based resin , which is a reaction product of ingredients comprising:a diisocyanate;a diol chain extender;a polyglycol; anda zwitterionic modifier or a combination of anionic and cationic modifiers incorporated into a backbone, as a side chain, or both of the polyurethane-based resin formed by the diisocyanate, the polyglycol, and the diol chain extender;the polyurethane-based resin having a hard segment content in a range of from 25% to 75% by weight and a soft segment content of the resin is in a range of from 75% to 25% by weight.2. The medical article of claim 1 , which is effective to reduce thrombus formation and/or bacterial biofilm formation.3. The medical article of claim 1 , wherein the anionic modifier comprises an anionic functional moiety of —SO claim 1 , —COO claim 1 , or combination thereof.4. The medical article of claim 3 , wherein the anionic modifier comprises one or more of: bis-1 claim 3 ,4-((2-hydroxypropoxy)-2-propoxy)-butane sulfonate sodium salt (SULFADIOL®-7Q); 2 claim 3 ,3-dihydroxypropane-1-sulfonate sodium salt; N claim 3 ,N-bis(2-hydroxyethyl)-2-aminoethanesulfonate sodium salt; 2 claim 3 ,2-bis(hydroxymethyl)propionic ...

ANTIBACTERIAL MICRO- AND NANOPARTICLES COMPRISING A CHLORHEXIDINE SALT, METHOD OF PRODUCTION AND USES THEREOF

Antimicrobial micro- or nano-particles comprising a chlorhexidine salt and an anion, and a method of making the antimicrobial micro- or nanoparticle, are disclosed. The anion in the salt is selected form oxoanions and partially hydrogenated oxoanions of phosphorus, carbon, nitrogen, and sulfur. 1. An antimicrobial micro- or nanoparticle comprising a chlorhexidine salt , wherein the anion in the salt is selected from:phosphates chosen from the homologous series of cyclic metaphosphates which begins with trimetaphosphate, and the homologous series of polyphosphates which begins with pyrophosphate; andthe oxoanions and partially hydrogenated oxoanions of nitrogen and sulphur.2. An antimicrobial micro- or nanoparticle of claim 1 , wherein the anion in the salt is either:selected from pyrophosphate, triphosphate, hexametaphosphate, nitrate and sulfate; orselected from the homologous series of cyclic metaphosphates.3. An antimicrobial micro- or nanoparticle comprising a chlorhexidine salt claim 1 , wherein the anion in the salt is selected from oxoanions and partially hydrogenated oxoanions of phosphorus claim 1 , carbon claim 1 , nitrogen claim 1 , and sulfur.4. An antimicrobial micro- or nanoparticle according to claim 3 , wherein the anion in the salt is selected from phosphates claim 3 , carbonate claim 3 , nitrate claim 3 , and sulfate.5. An antimicrobial micro- or nanoparticle of claim 3 , wherein the anion in the salt is either:selected from orthophosphate, pyrophosphate, triphosphate, hexametaphosphate, carbonate, nitrate and sulfate; orselected from the homologous series of cyclic metaphosphates.6. An antimicrobial micro- or nanoparticle according to claim 1 , wherein the salt is chlorhexidine hexametaphosphate.7. An antimicrobial micro- or nanoparticle according to claim 1 , wherein at least one dimension of the micro- or nanoparticle is from 20 to 200 nm.8. A colloidal suspension comprising the antimicrobial micro- or nanoparticle of .9. A colloidal suspension ...

Multilayer Medical Balloon

An expandable medical balloon including an inner layer formed of a poly (ether-block-amide) copolymer and an outer layer formed of a polyamide, the expandable medical balloon having a burst strength of greater than 50,000 psi, and to methods of making and using the same.

MEDICAL MATERIAL, AND MEDICAL DEVICE USING THE MEDICAL MATERIAL

The disclosure relates to a medical material including a copolymer having a repeating unit (A) represented by the following formula (1): 2. The medical material according to claim 1 , wherein in the formula (2) claim 1 , Ris a hydrogen atom or a methyl group claim 1 , Ris a Calkylene group claim 1 , and Ris a Calkyl group.3. The medical material according to claim 1 , wherein in the formula (1) claim 1 , Ris a methyl group claim 1 , Z is an oxygen atom or —NH— claim 1 , Ris a Calkylene group claim 1 , Rand Rare each independently a Calkyl group claim 1 , and Ris a Calkylene group.4. The medical material according to claim 1 , wherein the copolymer includes 0.6 to 7 mol % the repeating unit (A) and 99.4 to 93 mol % the repeating unit (B) (the total amount of the repeating unit (A) and the repeating unit (B) is 100 mol %).5. A medical device comprising:a substrate; and,{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'on a surface of the substrate, a coating layer containing the medical material according to .'}6. The medical material according to claim 1 , wherein the repeating unit (A) is selected from the group consisting of [2-(methacryloyloxy)ethyl]dimethyl-(3-sulfopropyl)ammonium hydroxide claim 1 , [2-(acryloyloxy)ethyl]dimethyl-(3-sulfopropyl)ammonium hydroxide claim 1 , {2-[(meth)acryloyloxy]ethyl)dimethyl-(2-sulfoethyl)ammonium hydroxide claim 1 , {2-[(meth)acryloyloxy]ethyl}diethyl-(2-sulfoethyl)ammonium hydroxide claim 1 , {2-[(meth)acryloyloxy]ethyl}diethyl-(3-sulfopropyl)ammonium hydroxide claim 1 , {3-[(meth)acryloyloxy]propyl}dimethyl-(2-sulfoethyl)ammonium hydroxide claim 1 , {3-[(meth)acryloyloxy]propyl}dimethyl-(3-sulfopropyl)ammonium hydroxide claim 1 , {3-[(meth)acryloyloxy]propyl}diethyl-(2-sulfoethyl)ammonium hydroxide claim 1 , {3-[(meth)acryloyloxy]propyl}diethyl-(3-sulfopropyl)ammonium hydroxide claim 1 , [3-(methacryloylamino)propyl]dimethyl(3-sulfopropyl)ammonium hydroxide claim 1 , [3-(acryloylamino)propyl]dimethyl(3-sulfopropyl)ammonium ...

REINFORCED BIOLOGICAL TISSUE

The present invention provides for an implantable medical device comprising a hybrid composite material including a first biological component such as an acellular tissue matrix and a second non-biological component for strengthening the device after implantation. 1. An implantable medical device , comprising:a composite material comprising:a sheet of an acellular tissue matrix; anda non-biological component including an upper portion, a lower portion, and a neck portion between the upper portion and the lower portion,wherein the sheet of the acellular tissue matrix wraps around the neck portion of the non biological component between the upper portion and the lower portion and covers at least a portion of a surface of the non-biological component to form an elongated composite having a predetermined target load capacity approximating the load capacity of a native human soft tissue to be replaced by the elongated composite,wherein at least one of (i) the upper portion of the non-biological component is folded over in the direction of the lower portion of the non-biological component or (ii) the lower portion of the non-biological component is folded over in the direction of the upper portion of the non-biological component, to overlap a portion of the wrapped sheet of the acellular tissue matrix with the non-biological component while maintaining a central portion of the wrapped sheet of the acellular tissue matrix exposed between the upper and lower portions of the non-biological component, andwherein the non-biological component has a higher tensile load capacity than the sheet of the acellular tissue matrix at the time of implantation, and the sheet of the acellular tissue matrix has a higher load capacity than the non-biological component after implantation and following growth of native cells within the acellular tissue matrix, such that the load capacity of the composite material is within the target load capacity range at the time of implantation and also ...

Drug delivery composition

There is provided a non-water soluble drug delivery composition comprising a conjugate and a polymer matrix wherein exposure of the composition to electromagnetic radiation at a suitable pre-determined wavelength and intensity induces release of the active ingredient from the composition. The conjugate is attached to the polymer matrix through non-covalent interactions. There is also provided a drug delivery apparatus formed from the drug delivery composition.

Liquid Injectable Copolymer

The invention provides liquid injectable copolymers of TMC and HTMC that are degradable in vivo. Degradation can be tailored by adjusting the amount of HTMC in the copolymer, the initial molecular weight of the copolymer, and the characteristics of the initiator used in its preparation. Specifically, the degradation rate increases as the amount of HTMC incorporated into the copolymer increases, as the molecular weight of the copolymer decreases, and as the hydrophobicity of the initiator decreases. Moreover, the degradation yields products such as glycerol and carbon dioxide that are non-toxic in vivo, and which will not cause a substantive change in tissue pH upon implantation in vivo. The copolymers may be used in applications such as drug delivery and as coatings. 1. An injectable , degradable , liquid copolymer , comprising:trimethylene carbonate (TMC);5-hydroxy trimethylene carbonate (HTMC); andan initiator.2. The injectable claim 1 , degradable claim 1 , liquid copolymer of claim 1 , wherein:a degradation rate of the copolymer is controlled according to at least one of a monomer composition, an initiator, and a molecular weight (MW) of the copolymer, andthe copolymer remains as a viscous liquid depot, and gradually degrades according to the controlled degradation rate.3. The injectable claim 1 , degradable claim 1 , liquid copolymer of claim 1 , wherein the degradation rate of the copolymer is controlled according to a ratio of TMC:HTMC.4. The injectable claim 3 , degradable claim 3 , liquid copolymer of claim 3 , wherein the ratio of TMC:HTMC is from 15:1 to 1:9.5. The injectable claim 1 , degradable claim 1 , liquid copolymer of claim 1 , wherein the viscosity of the copolymer is related to an amount of the initiator;wherein the amount of the initiator is selected to be from about 1% w/w to about 50% w/w of the MW of the copolymer.6. The injectable claim 1 , degradable claim 1 , liquid copolymer of claim 1 , wherein the MW of the copolymer is from about 500 ...

Biocompatible copolymer, curable composition, biocompatible coating layer and biocompatible device including the same

A biocompatible copolymer includes a phosphorylcholine-containing structural unit represented by formula (I), a siloxy-containing structural unit represented by formula (II), and a photoreactive structural unit represented by formula (III), wherein each of the substituents is given the definition as set forth in the Specification and Claims. A curable composition, a biocompatible coating layer, and a biocompatible device containing the biocompatible copolymer are also disclosed.

METHODS AND DEVICES FOR CELLULAR TRANSPLANTATION

Devices and methods for transplanting cells in a host body are described. The cell comprises a porous scaffold that allows ingrowth of vascular and connective tissues, a plug or plug system configured for placement within the porous scaffold, and a seal configured to enclose a proximal opening in the porous scaffold. The device may further comprise a cell delivery device for delivering cells into the porous scaffold. The method of cell transplantation comprises a two step process. The device is incubated in the host body to form a vascularized collagen matrix around a plug positioned within the porous scaffold. The plug is then retracted from the porous scaffold, and cells are delivered into the vascularized space created within the porous scaffold. 185-. (canceled)86. A device for implanting cells in a host body , comprising:a porous scaffold comprising a polypropylene mesh forming the walls of at least one chamber, wherein the chamber comprises an opening at either or both of a proximal end and a distal end of the chamber, wherein the proximal end and the distal end are separated by a lumen that is bounded by the walls, and wherein the porous scaffold has pores sized to facilitate growth of vascular and connective tissues around and through the walls of the at least one chamber;at least one removable, non-porous two-plug system configured to be positioned within the lumen of the at least one chamber, wherein the two-plug system comprises an outer plug configured to be positioned within the lumen of the at least one chamber and an inner plug configured to be positioned within the outer plug, and wherein the two-plug system extends along the lumen of the chamber;at least one seal configured to enclose either or both the proximal end and the distal end of the chamber; andcells within the chamber, wherein the cells comprise differentiated stem cells or encapsulated cells.87. The device of claim 86 , wherein the cells are encapsulated in alginate claim 86 , a ...

IRRIGATION RESISTANT COMPOSITIONS FOR REGENERATION OF HARD TISSUES AND METHODS OF USING THE SAME

An irrigation resistant bone repair composition including a biocompatible or bioactive bone repair material comprising borate, and poly(glycerol sebacate), wherein the composition, upon implantation into a surgical site, maintains position and does not displace upon irrigation of the surgical site, is described. Also, methods for treating a bone having a bone gap or a bone defect with the composition as well as kits that include the composition, are provided. 1. A bone repair composition comprising:a porous biocompatible or bioactive bone repair material comprisingborate, andpoly(glycerol sebacate),wherein the composition, upon implantation into a surgical site, maintains position and does not displace upon irrigation of the surgical site.2. The bone repair composition of claim 1 , wherein the weight ratio of the poly(glycerol sebacate) is 1%-99% relative to the weight of the bone repair composition.3. The bone repair composition of claim 1 , wherein the composition is osteoconductive.4. The bone repair composition of claim 1 , wherein the composition is osteostimulative.5. The bone repair composition of claim 1 , wherein the bone repair material is a borate bioactive glass or ceramic.6. The bone repair composition of claim 5 , wherein the borate bioactive glass is a melt-derived borate bioactive glass or a sol-gel derived borate bioactive glass.7. The bone repair composition of claim 6 , wherein the bioactive glass is in the form of a particle claim 6 , sphere claim 6 , fiber claim 6 , mesh claim 6 , sheet or a combination of these forms.8. The bone repair composition of claim 6 , wherein the bioactive glass is in the amorphous or crystalline form claim 6 , or a combination of these forms.9. The bone repair composition of claim 5 , wherein the composition forms a synthetic bone-grafting putty claim 5 , paste claim 5 , gel claim 5 , strip or waxy solid.10. The bone repair composition of claim 5 , wherein the composition is in an injectable form.11. The bone repair ...

Suture washer

A suture washer construct for fixation of soft tissue to bone, or of soft tissue to soft tissue. The suture washer provides enhanced fixation and soft tissue protection. The washer consists of a cannulated metal washer with a series of through passages running around the body of the washer, to allow one or more flexible strands (for example, one or more sutures) to extend through the passages. The washer is threaded over a fixation device (screw or anchor) before insertion. Once the fixation device (screw or anchor) is inserted, the surgeon has the ability to pass the flexible strand (suture) as with a typical anchor.

Ion Exchange Absorbent Systems, Apparatuses, And Methods

Systems, methods, and apparatuses for increasing liquid absorption are described. Some embodiments may include a dressing having an absorbent layer containing super-absorbent material as well as ionic-exchange media (IEM). In some embodiments, the absorbent layer may include absorbent fibers. The absorbent fibers may each include a super-absorbent core surrounded by a water-permeable layer onto which ionic-exchange media (IEM) may be grafted. As liquid comes into contact with the IEM, its ionic nature may be reduced, therefore protecting the absorbent qualities of the super-absorbent material. 141.-. (canceled)42. A system for treating a tissue site , comprising:a reduced-pressure source; an absorbent material adapted to absorb fluid from the tissue site, and', 'an ion-exchange media adapted to reduce an ionic concentration of the fluid; and, 'an absorbent layer adapted to be in fluid communication with the reduced-pressure source, the absorbent layer comprisinga drape adapted to cover the absorbent layer.43. The system of claim 42 , further comprising a container having an absorbent sheet disposed therein claim 42 , and adapted to be in fluid communication with the tissue site and the reduced-pressure source.44. The system of claim 42 , further comprising a manifold adapted to be positioned between the absorbent layer and the tissue site.45. The system of claim 42 , wherein the ion-exchange media comprises porous beads formed from cross-linked polymers doped or grafted with acidic polymers.46. The system of claim 45 , wherein the cross-linked polymers comprise polystyrene and the acidic polymers comprise poly (2-acrylamido-2-methyl-1-propanesulfonic acid) and poly (acrylamido-N-propyltrimethylammonium chloride).47. The system of claim 42 , wherein the ion-exchange media comprises an alkaline polymer.48. The system of claim 47 , wherein the alkaline polymer is poly(acrylamido-N-propyltrimethylammonium chloride).49. The system of claim 42 , wherein the ion-exchange ...

AMINO ACID DERIVATIVES AND ABSORBABLE POLYMERS THEREFROM

The present invention relates to the discovery of new class of hydrolysable amino acid derivatives and absorbable polyester amides, polyamides, polyepoxides, polyureas and polyurethanes prepared therefrom. The resultant absorbable polymers are useful for drug delivery, tissue engineering, tissue adhesives, adhesion prevention, bone wax formulations, medical device coatings, stents, stent coatings, highly porous foams, reticulated foams, wound care, cardiovascular applications, orthopedic devices, surface modifying agents and other implantable medical devices. In addition, these absorbable polymers should have a controlled degradation profile. 118-. (canceled)20. The medical or surgical article of claim 19 , wherein alkyl is selected from isopentyl and neopentyl.21. The medical or surgical article of claim 19 , wherein the compound is of formula N.22. The medical or surgical article of claim 21 , wherein R″ is a biologically active substance selected from: Capsaicin claim 21 , Triclosan claim 21 , Chloroxylenol claim 21 , Clioquinol claim 21 , Nitroxoline claim 21 , Oxyquinoline claim 21 , Paracetamol claim 21 , Tioxolone claim 21 , Diflunisal claim 21 , Naproxen claim 21 , Diclofenac claim 21 , Vitamin E claim 21 , Butylated hydroxytoluene claim 21 , and Butylated hydroxylanisol.24. The medical or surgical article of claim 19 , wherein the compound is of formula V.25. The medical or surgical article of claim 24 , wherein R″ is a biologically active substance selected from: Capsaicin claim 24 , Triclosan claim 24 , Chloroxylenol claim 24 , Clioquinol claim 24 , Nitroxoline claim 24 , Oxyquinoline claim 24 , Paracetamol claim 24 , Tioxolone claim 24 , Diflunisal claim 24 , Naproxen claim 24 , Diclofenac claim 24 , Vitamin E claim 24 , Butylated hydroxytoluene claim 24 , and Butylated hydroxylanisol.27. The medical or surgical article of claim 19 , wherein the surgical article is a tissue adhesive.28. The medical or surgical article of claim 19 , wherein the surgical ...

Amino acid derivatives and absorbable polymers therefrom

The present invention relates to the discovery of new class of hydrolysable amino acid derivatives and absorbable polyester amides, polyamides, polyepoxides, polyureas and polyurethanes prepared therefrom. The resultant absorbable polymers are useful for drug delivery, tissue engineering, tissue adhesives, adhesion prevention, bone wax formulations, medical device coatings, stents, stent coatings, highly porous foams, reticulated foams, wound care, cardiovascular applications, orthopedic devices, surface modifying agents and other implantable medical devices. In addition, these absorbable polymers should have a controlled degradation profile.

Devices and methods for inhibiting or preventing colonization of fluid flow networks by microorganisms

The invention includes novel devices and methods for inhibiting or preventing colonization of fluid flow networks by bacteria that have upstream surface motility. In certain aspects, the devices and methods of the invention prevent or minimize undesirable bacterial colonization of medical devices and/or treat or prevent bacterial infections.

Methods, Systems, and Devices Relating to Directional Eluting Implantable Medical Devices

Implantable medical devices may directionally elute a first therapeutic agent that promotes the growth of endothelial cells and a second therapeutic agent that inhibits the growth of smooth muscle cells. In some embodiments, implantable medical devices may elute a first therapeutic agent such as an anti-proliferative drug from an abluminal side of the implantable medical device and a second therapeutic agent such as an endothelialization agent from a luminal side of the implantable medical device.

DRY EYE TREATMENT DEVICES AND METHODS

Devices can be implanted in an eye to treat a dry eye condition. The devices include a body defining a lumen and having first and second ends and external and lumenal surfaces. The body has a length sufficient to provide fluid communication between the anterior chamber and tear film of the eye through the lumen when the device is implanted in the sclera. In some embodiments, the device is filterless. In some embodiments, a filter is included. The dry eye treatment devices provided herein prevent bacterial ingress, provide outflow resistance to retain a normal intraocular pressure, and provide moisture (e.g., aqueous humor) to an otherwise dry eye. Methods of treating a dry eye condition wherein the device is implanted in the sclera of an afflicted eye are also described. 1. A device for treating an eye condition , the device comprising:a body having a distal end portion, a proximal end portion, and a mid-body portion extending between the distal end portion and the proximal end portion, the body defining a lumen extending along the body between the distal end portion and the proximal end portion, the body having external and lumenal surfaces, the body having a longitudinal length sufficient to provide fluid communication between an anterior chamber and a tear film of the eye through the lumen when the device is implanted in a sclera of the eye, the mid-body portion being laterally narrower than some portions of each the distal end portion and the proximal end portion.2. The device of claim 1 , wherein a proximal edge of the proximal end portion is radiused.3. The device of wherein a maximum longitudinal length of the body in comparison to a maximum lateral width of the body is a ratio between 1:1 to 3:1.4. The device of claim 1 , wherein a distal edge of the distal end portion is radiused.5. The device of claim 1 , wherein the distal end portion is laterally flared.6. The device of claim 1 , wherein the external surface of the device is configured to provide ...

Demineralized Bone Matrix

A demineralized bone matrix is produced by a process in which a bone body is placed in a first processing solution comprising an acid to demineralize the bone body. The bone body is periodically removed from the first solution at specific time intervals to perform at least one test, such as a compression test, on a mechanical property of the bone body. When the test yields a desired result, the bone body is exposed to a second processing solution that is less acidic than the first, thus minimizing the exposure of the bone body to the harsh acidic conditions of the demineralization phase of the process. 1. A demineralized bone matrix having greater than about 60 pg/g of bone of insulin-like growth factor-1 (IGF-1) , wherein the matrix contains less than 2 percent by weight residual content of a mineral.2. The demineralized bone of claim 1 , wherein at least one dimension of the matrix is at least 2 mm.3. The demineralized bone of claim 1 , wherein the matrix is a sponge-like bone graft matrix.4. The demineralized bone of claim 1 , wherein the matrix is compressible to 5 to 60 percent of an original shape of the matrix when between 10 and 1000 grams-force/cmof force is applied to the matrix.5. The demineralized bone matrix of claim 1 , wherein the matrix is infiltrated with stem cells.6. The demineralized bone matrix of claim 1 , wherein the matrix is coated with stem cells.7. The demineralized bone matrix of claim 1 , wherein the bone matrix comprises an open porous structure.8. The demineralized bone matrix of claim 1 , wherein the bone matrix is not in a carrier.9. The demineralized bone matrix of claim 1 , further comprising a secondary material selected from the group consisting of bone void filler claim 1 , a metal claim 1 , a plastic and a composite.10. The demineralized bone matrix of claim 1 , wherein the matrix is reversibly deformable.11. The demineralized bone matrix of claim 1 , wherein a structure of the matrix will not dissolve with irrigation.12. The ...

USE OF BACTERIAL POLYSACCHARIDES FOR BIOFILM INHIBITION

A method comprises preventing or inhibiting bacterial adhesion and/or bacterial biofilm development by treating a substrate with a composition of a soluble group II capsular polysaccharide obtained from a bacterial strain. 124-. (canceled)25. A medical or industrial device comprising a surface coated with a composition comprising a mixture of soluble group II capsular polysaccharides isolated from a cell-free supernatant of a culture of a bacterial strain comprising a group II capsule , wherein the composition inhibits bacterial adhesion and/or bacterial biofilm development on the device.28E. coli, H. influenzaeN. meningitidis.. The medical or industrial device of claim 25 , wherein the bacterial strain is a strain of a bacteria selected from the group consisting of and29. The medical or industrial device of claim 25 , wherein the surface is dip coated with the composition.30. The medical or industrial device of claim 25 , wherein the composition is applied to the surface as a sheet.31. The medical or industrial device of claim 25 , wherein the surface is painted with the composition.32. The medical or industrial device of claim 25 , wherein coated device is heat sterilized.33. The device of claim 25 , wherein the device is an industrial device.34. The industrial device of claim 33 , wherein the device is a pipe claim 33 , tube claim 33 , or valve.35. The industrial device of claim 33 , wherein the device is an air-cooled tower claim 33 , warm water system claim 33 , coolant circuit claim 33 , silo claim 33 , fermenter claim 33 , colander claim 33 , or furniture element.36. The device of claim 25 , wherein the device is a medical device.37. The medical device of claim 36 , wherein the device is a non-disposable dental tool.38. The medical device of claim 36 , wherein the device is a non-disposable surgical tool.39. The medical device of claim 36 , wherein the medical device is an indwelling implant.40. The medical device of claim 39 , wherein the device is a dental ...

MATERIALS AND METHODS

The invention relates to methods of controlling orientation of direct covalent binding of a peptide to a polymer substrate surface, to surfaces with peptides directly covalently bound thereto in a manner where the orientation of binding is controlled as well as to devices comprising such substrates. In particular the invention relates to A method of controlling predominant orientation of direct covalent binding of one or more peptides to a polymer substrate surface comprising: (a) exposing the surface to energetic ion treatment to generate a plurality of activated sites comprising reactive radical species; (b) incubating the surface with one or more peptide/s that exhibit or can be induced to exhibit a dipole moment and manipulating the electric field environment and/or charge of said surface and/or of said peptide/s during said incubating; wherein predominant orientation of direct covalent binding of said peptide/s to said surface is thereby controlled. 2. The method of wherein said energetic ion treatment is plasma immersion ion implantation (PIII) or ion beam exposure of an existing polymer substrate surface.3. The method of wherein said energetic ion treatment is energetic ion bombardment during deposition of a plasma polymer.4. The method of wherein the polymer comprises one or more of polyolefins claim 1 , blends of polyolefins with other polymers or rubber claim 1 , polyethers claim 1 , polyamides claim 1 , polyimides claim 1 , polycarbonates claim 1 , halogenated polymers claim 1 , aromatic polymers claim 1 , ketone polymers claim 1 , methacrylate polymers claim 1 , polyesters and copolymers.5. (canceled)6. The method of wherein the substrate takes the form of a block claim 1 , sheet claim 1 , film claim 1 , tube claim 1 , strand claim 1 , fibre claim 1 , piece or particle claim 1 , powder claim 1 , shaped article claim 1 , woven fabric or massed fibre pressed into a sheet.7. The method of wherein the polymer comprises a surface of a device.8. (canceled)9. ...

HYPERTONIC ANTIMICROBIAL THERAPEUTIC COMPOSITIONS

Therapeutic compositions, primarily for topical application, and methods of making and using the composition. Pharmaceutical compositions formulated for specific forms of administration are also provided. 112-. (canceled)13. A therapeutic composition comprising:a) a chloride salt;b) a source of bicarbonate; andc) a source of hypochlorite;wherein the amount of the salt in the composition is sufficient to render the composition hypertonic; and, wherein the composition is alkaline.14. The composition of claim 13 , whereinthe concentration of the chloride salt in the composition is at least 200 mM;the concentration of the source of bicarbonate in the composition is at least 4.9M;the concentration of the source of hypochlorite is at least 0.5% (w/w).15. The therapeutic composition of claim 13 , wherein the concentration of salt in the composition is in the range of from about 4M to about 8M.16. The composition of claim 13 , wherein the chloride salt is selected from the group consisting of sodium chloride and potassium chloride.17. The composition of claim 13 , wherein the source of bicarbonate is selected from the group consisting of sodium bicarbonate claim 13 , calcium bicarbonate claim 13 , ammonium bicarbonate and sodium percarbonate.18. The composition of claim 13 , wherein the source of hypochlorite is N-chloro-tosylamide.19. The composition of claim 13 , further comprising an antimicrobial agent.20. The composition of claim 19 , wherein the antimicrobial agent is selected from the group consisting of biguanides claim 19 , bisbiguanides claim 19 , triguanides claim 19 , and analogues thereof.21. The composition of claim 19 , wherein the antimicrobial agent is chlorhexidine.22. The therapeutic composition of claim 13 , wherein the composition further comprises at least one compound selected from the group consisting of an oxygen-producing compound claim 13 , a poloxamer claim 13 , a surfactant and a polyhydroxy acid.23. The therapeutic composition of claim 22 , ...

PROGESTERONE-CONTAINING COMPOSITIONS AND DEVICES

Progesterone-containing compositions and devices that can maintain opening of a body passageway are described. One aspect of the invention provides a therapeutically effective (e.g., relaxative, anti-oxidative, anti-restenotic, anti-angiogenic, anti-neoplastic, anti-cancerous, anti-precancerous and/or anti-thrombotic) composition or formulation containing progesterone and optionally vitamin E and/or conjugated linoleic acid. Another aspect of the invention provides a drug eluting device, such as a drug eluting stent, with at least one coating layer comprising a progesterone composition that can minimize or eliminate inflammation, thrombosis, restenosis, neo-intimal hyperplasia, rupturing of vulnerable plaque, and/or other effects related to device implantation, treatment, or interaction. Other aspects of the invention provide for methods of using such compositions, formulations, and devices. 1. A drug eluting medical device comprising:a medical device;an eluting mechanism selected from the group consisting of a coating, reservoir, pore, duct, channel, chamber, side-port, and lumen; anda composition consisting essentially of (i) progesterone or a progesterone analog or (ii) progesterone or a progesterone analog and one or more of vitamin E and conjugated linoleic acid; the medical device comprises the eluting mechanism;', 'the eluting mechanism elutes the composition;', 'the progesterone is present in a therapeutically effective amount; and', 'the progesterone is eluted in vivo., 'wherein'}2. The device of claim 1 , wherein:the eluting mechanism is proximal to, distal to, lateral to, underneath, embedded within or on the device; andthe eluting mechanism elutes progesterone in vivo.3. The device of claim 1 , comprising at least one coating layer; wherein:the at least one coating layer comprises the composition; andthe at least one coating layer is formed on at least a portion of a surface of the medical device.4. The device of claim 1 , wherein the composition ...

ABSORBENT ARTICLE

An absorbent article includes a liquid-permeable top sheet, a liquid-impermeable back sheet, and an absorbent body that is arranged between the top sheet and the back sheet. The absorbent article further includes a pair of flaps provided to both sides of the absorbent article in a lengthwise direction, a first area containing a blood lubricity-imparting agent, and a second area containing a blood lubricity-imparting agent. The first and second areas are provided to at least an excretory orifice contact area of the top sheet and to the pair of flaps. A basis weight of the blood lubricity-imparting agent in the first area is greater than the basis weight of the blood lubricity-imparting agent in the second area. 1. An absorbent article having a liquid-permeable top sheet , a liquid-impermeable back sheet and an absorbent body between the top sheet and the back sheet ,wherein the absorbent article comprises, at both sides in a lengthwise direction, a pair of flaps for anchoring the absorbent article to a clothing of a wearer,{'sup': '2', 'at least an excretory opening contact region of the top sheet and the pair of flaps have a blood slipping agent-containing first region and blood slipping agent-containing second regions each containing a blood slipping agent with a kinematic viscosity of 0.01 to 80 mm/s at 40° C., a water holding percentage of 0.01 to 4.0 mass % and a weight-average molecular weight of less than 1,000,'}a basis weight of the blood slipping agent in the blood slipping agent-containing first region in the excretory opening contact region of the top sheet is greater than a basis weight of the blood slipping agent in the blood slipping agent-containing second regions of the pair of flaps.2. The absorbent article according to claim 1 , wherein the blood slipping agent further has an IOB of 0.00 to 0.60.3. The absorbent article according to claim 1 , wherein the pair of flaps are folded over onto the top sheet.4. The absorbent article according to claim 1 ...

ABSORBENT ARTICLE HAVING A LOTIONED TOPSHEET

The absorbent article of the invention has a liquid impervious backsheet and a liquid pervious topsheet joined to the backsheet. The topsheet has an inner surface oriented toward the interior of the absorbent article and an outer surface oriented toward the skin and hair of the wearer when the absorbent article is being worn and an absorbent core positioned between the topsheet and the backsheet. At least a portion of the topsheet outer surface comprises an effective amount of a lotion coating which is semi-solid or solid at 20 degrees C., the lotion coating comprising: 1. An absorbent article comprising:A) a liquid impervious backsheet; (i) from about 10 to about 95% of a substantially water free emollient, said emollient comprising a member selected from the group consisting of polysiloxane compounds;', '(ii) from about 5% to about 90% of an agent capable of immobilizing said emollient on said outer surface of the topsheet, said immobilizing agent being miscible with said emollient, said immobilizing agent having a melting point of at least about 35 degrees C.; and, 'B) a liquid pervious topsheet joined to said backsheet, said topsheet having an inner surface oriented toward the interior of said absorbent article and an outer surface oriented toward the skin and hair of the wearer when said absorbent article is being worn, wherein at least a portion of said topsheet outer surface comprises an effective amount of a lotion coating having a HLB value below 7, said lotion coating comprisingC) an absorbent core positioned between said topsheet and said backsheet.3. The absorbent article of wherein said article is selected from the group consisting of feminine hygiene garments claim 1 , sanitary napkins claim 1 , pantiliners claim 1 , and interlabial devices.4. The absorbent article of wherein said emollient contains about 5% or less water and comprises a petroleum based emollient selected from the group consisting of mineral oil claim 1 , petrolatum claim 1 , and ...

SOLUBLE BACTERIAL AND FUNGAL PROTEINS AND METHODS AND USES THEREOF IN INHIBITING AND DISPERSING BIOFILM

The present disclosure relates to methods of treating or preventing a biofilm-related infection and methods of preventing and treating biofilm formation on indwelling medical devices, implants, and non-medical surfaces comprising administering at least one soluble microbial protein that is encoded by an exopolysaccharide biosynthetic operon or functional gene cluster, wherein the protein comprises a glycosyl hydrolase domain. The present disclosure further provides particular soluble glycosyl hydrolases and compositions thereof. 1. A method of treating or preventing a biofilm-related infection comprising administering at least one , at least two of , at least three of , at least four of , at least five of , or all of: (i) a soluble protein comprising a Sph3 GH domain , (ii) a soluble protein comprising a PelA GH domain , (iii) a soluble protein comprising a BpsB GH domain , (iv) a soluble protein comprising a PgaB GH domain , (v) a soluble protein comprising a PslG glycosyl hydrolase (GH) domain and (vi) a soluble protein comprising an Ega3 GH domain , or orthologs thereof , to an animal or plant in need thereof.2. The method of claim 1 , wherein(a) the soluble protein comprising a Sph3 GH domain comprises amino acids 52 to 298 of the Sph3 sequence deposited into GenBank under accession no. EAL92786.1 or a glycosyl hydrolase variant thereof;(b) the soluble protein comprising a Sph3 GH domain ortholog comprises amino acids 54 to 304 of the Sph3 sequence deposited into Genbank under accession no. EAW09379.1 or a glycosyl hydrolase variant thereof;(c) the soluble protein comprising a Sph3 GH domain ortholog comprises amino acids 43 to 299 of the Sph sequence deposited into Genbank under accession no. EAA63523.1 or a glycosyl hydrolase variant thereof;(d) the soluble protein comprising a PelA GH domain comprises amino acids 47 to 303 of the PelA sequence deposited into GenBank under accession no. AAG06452 1 or amino acids 35-291 of the PelA sequence deposited into ...

PEPTIDE-COATED CALCIUM PHOSPHATE PARTICLES

The invention features methods and compositions for (i) controlling the amount of peptide bound to calcium phosphate particles; and (ii) for tightly binding peptide to the surface of calcium phosphate particles. The methods and compositions can be useful for preparing implants useful for promoting bone deposition at the site of implantation, and for repairing a variety of orthopedic conditions. 14.-. (canceled)5. A composition comprising hydroxyapatite particles coated with P-15 peptide , wherein the P-15 peptide is tightly bound to the surface of the hydroxyapatite particles and wherein the concentration of P-15 peptide bound to the surface of the hydroxyapatite particles is from 260 to 1 ,200 ng of P-15 per gram of hydroxyapatite particles.6. The composition of claim 5 , wherein said hydroxyapatite particles are anorganic bone mineral particles.78.-. (canceled)9. A method for coating calcium phosphate particles with a peptide claim 5 , said method comprising:(i) combining the calcium phosphate particles with a first aqueous salt solution having an osmolarity value greater than 290 mOsm and a pH of between 6.5 and 8.5 to produce pretreated calcium phosphate particles;(ii) combining the pretreated calcium phosphate particles with a second aqueous salt solution containing the peptide and having an osmolarity value greater than 290 mOsm and a pH of between 6.5 and 8.5 to produce coated calcium phosphate particles; and(iii) separating the coated calcium phosphate particles from the second aqueous salt solution.10. A method for coating calcium phosphate particles with a peptide claim 5 , said method comprising:(i) providing pretreated calcium phosphate particles prepared by combining the calcium phosphate particles with a first aqueous salt solution having an osmolarity value greater than 290 mOsm and a pH of between 6.5 and 8.5;(ii) combining the pretreated calcium phosphate particles with a second aqueous salt solution containing the peptide and having an osmolarity ...

Reinforced Biological Tissue

The present invention provides for an implantable medical device comprising a hybrid composite material including a first biological component such as an acellular tissue matrix and a second non-biological component for strengthening the device after implantation.

ABSORBENT ARTICLE

An individually packaged absorbent article has a pair of flaps for securing the absorbent article to clothing of a wearer. The absorbent article is folded multiple times along multiple folding axes such that the pair of flaps is folded over a liquid-permeable top sheet and the top sheet faces inward. The top sheet has a blood lubricating agent containing region, which contains a predetermined blood lubricating agent, in an area which overlaps with the pair of flaps in the thickness direction of the absorbent article. Moreover, the absorbent article is provided with a spacer for forming a space between the pair of flaps and the blood lubricating agent containing region of the top sheet. 1. An absorbent article that is an individually packaged absorbent article having a liquid-permeable top sheet , a liquid-impermeable back sheet , an absorbent body between the top sheet and the back sheet , and a pair of flaps situated on both sides in a lengthwise direction of the absorbent article for anchoring of the absorbent article to a clothing of a wearer ,wherein the absorbent article is folded several times along a plurality of folding axes, so that the pair of flaps overlap onto the top sheet and the top sheet is on an inner side,{'sup': '2', 'the liquid-permeable top sheet has a blood slipping agent-containing region containing a blood slipping agent with a kinematic viscosity of 0.01 to 80 mm/s at 40° C., a water holding percentage of 0.01 to 4.0 mass % and a weight-average molecular weight of less than 1,000, in a region where it overlaps with the pair of flaps in a thickness direction of the absorbent article, and'}the absorbent article has a spacer for forming a space between the pair of flaps and the blood slipping agent-containing region of the top sheet.2. The absorbent article according to claim 1 , wherein the blood slipping agent further has an IOB of 0.00 to 0.60.3. The absorbent article according to claim 1 , wherein the spacer is disposed along approximately ...

Multilayer Medical Balloon

An expandable medical balloon including an inner layer formed of a poly (ether-block-amide) copolymer and an outer layer formed of a polyamide, the expandable medical balloon having a burst strength of greater than 50,000 psi, and to methods of making and using the same. 1. An expandable medical balloon comprising:an inner layer formed of a polymer material having a Shore D hardness of about 25D to about 75D; andan outer layer formed of a polymer material having a Shore D hardness of greater than about 75D;and wherein the expandable medical balloon has a burst strength of greater than about 45,000 psi.2. The expandable medical balloon of claim 1 , wherein the burst strength is greater than about 47 claim 1 ,500 psi.3. The expandable medical balloon of claim 1 , wherein the burst strength is greater than about 50 claim 1 ,000 psi.4. The expandable medical balloon of claim 1 , wherein the inner layer is formed from a poly(ether-block-amide) copolymer.5. The expandable medical balloon of claim 1 , wherein the inner layer is formed of a polymer material having a Shore D hardness of about 50D to about 70D.6. The expandable medical balloon of claim 1 , wherein the outer layer is formed of a polymer material having a Shore D hardness of 80D or greater.7. The expandable medical balloon of claim 1 , wherein the wall thickness of the balloon is about 10 microns to about 30 microns.8. The expandable medical balloon of any of claim 1 , further comprising a lubricious coating on at least a portion of the outer layer.9. An expandable medical balloon comprising:an inner layer formed of a poly(ether-block-amide) copolymer; andan outer layer formed from a polymer material having a higher tensile set than the poly(ether-block-amide) copolymer of the inner layer; andwherein the expandable medical balloon has a calculated burst strength of greater than 45,000 psi.10. The expandable medical balloon of claim 9 , wherein the outer layer is formed of a polymer material having a Rockwell ...

Polymer metal-organic framework composites

Provided herein are polymer and metal organic frameworks (MOFs) composites, and methods of use and preparation thereof. In particular, Poly(polyethyleneglycol citrate-co-N-isopropylacrylamide) (PPCN) and copper MOF composites are provided.

PEEL AND PLACE DRESSING FOR NEGATIVE-PRESSURE TREATMENT

A dressing for treating a tissue site with negative pressure may comprise a tissue interface comprising a three-dimensional textile of polyester fibers and a polymer coating on the polyester fibers. In some examples, the three-dimensional textile may be a three-dimensional weave of polyester fibers, and the polymer coating may be hydrophobic. In more particular embodiments, the polymer coating may be silicone or polyethylene, for example. The dressing may additionally include a drape disposed over the tissue interface and a port fluidly coupled to the tissue interface through the drape. The tissue interface may be applied over a tissue site, and therapeutic levels of negative pressure may be applied to the tissue site through the tissue interface. 1. A dressing for treating a tissue site with negative pressure , the dressing comprising:a tissue interface comprising a three-dimensional textile of polyester fibers; anda polymer coating on the polyester fibers.2. The dressing of claim 1 , wherein the three-dimensional textile is a three-dimensional weave of polyester fibers.3. The dressing of claim 1 , wherein the polymer is hydrophobic.4. The dressing of claim 1 , wherein the three-dimensional textile has a weight of about 470 grams per square meter.5. The dressing of claim 1 , wherein the three-dimensional textile further comprises cotton fibers.6. The dressing of claim 4 , wherein the three-dimensional textile has a weight of about 650 grams per square meter.7. The dressing of claim 1 , wherein the three-dimensional textile has a weight of about 380 grams per square meter.8. The dressing of claim 7 , wherein the polyester fibers are elastic in at least two dimensions.9. The dressing of claim 7 , wherein the polymer coating is discontinuous.10. The dressing of claim 8 , wherein the polymer is silicone.11. The dressing of claim 8 , wherein the polymer is polyethylene.12. The dressing of claim 1 , further comprising a sealing layer adjacent to the tissue interface ...

Silicone Gel-Coated Wound Dressing

A wound dressing product comprising: a substrate layer having an upper surface and a lower surface; a tacky silicone coating composition present on said upper surface and on said lower surface; and upper and lower release sheets covering said substrate and said tacky silicone coating composition on said upper and lower surfaces, respectively, and adhered to said surfaces by said tacky silicone coating composition, wherein said upper surface is less tacky than said lower surface whereby said upper release sheet can be removed from said upper surface more readily than said lower release sheet can be removed from said lower surface. Also provided are methods for making such dressings. 114.-. (canceled)15. A wound dressing product comprising:a substrate layer having an upper surface and a lower surface;a tacky silicone coating composition present on said upper surface and on said lower surface; andupper and lower release sheets covering said substrate layer and said tacky silicone coating composition on said upper surface and said lower surface, respectively, and adhered to said surfaces by said tacky silicone coating composition, wherein said upper surface is less tacky than said lower surface whereby said upper release sheet can be removed from said upper surface more readily than said lower release sheet can be removed from said lower surface.16. The wound dressing product of claim 15 , wherein an array of apertures extends through said silicone coating composition and said substrate layer.17. The wound dressing product of claim 15 , wherein said substrate layer comprises or consists essentially of a woven claim 15 , nonwoven or knitted mesh.18. The wound dressing product of claim 15 , wherein the tackiness of said lower surface as measured by a loop tack test is at from 20% to 100% greater than the tackiness of said upper surface.19. The wound dressing product of claim 15 , wherein said silicone coating composition on said upper surface and said lower surface is ...

NEURONAL REPLACEMENT AND REESTABLISHMENT OF AXONAL CONNECTIONS

The present invention provides compositions and methods for modulation of neuronal networks in the CNS and/or PNS. In certain embodiments, the invention includes modulation of existing networks or restoring one or more damaged or lost axonal connections. In one embodiment, the invention comprises a tissue-engineered composition comprising an elongated tubular construct having at least one neuron and axon extending through the core of the construct. 1. A composition for modulating the activity of neurological network comprising:an elongated tubular construct having a first end and a second end, the construct comprising a tubular body having an outer surface and an inner surface defining a luminal core; andat least one axon extending through at least a portion of the core.2. The composition of claim 1 , wherein the tubular body is a hydrogel.3. The composition of claim 2 , wherein the hydrogel comprises at least one biopolymer claim 2 , wherein the at least one biopolymer is at least one selected from the group consisting of hyaluronan claim 2 , chitosan claim 2 , alginate claim 2 , collagen claim 2 , dextran claim 2 , pectin claim 2 , carrageenan claim 2 , polylysine claim 2 , gelatin and agarose.4. The composition of claim 1 , wherein the luminal core comprises at least one extracellular matrix protein.5. The composition of claim 4 , wherein the at least one extracellular matrix protein is at least one selected from the group consisting of collagen claim 4 , fibronectin claim 4 , fibrin claim 4 , hyaluronic acid claim 4 , elastin claim 4 , and laminin.6. The composition of claim 1 , wherein the construct has an outer diameter from about 500 μm to about 1 mm.7. The composition of claim 1 , wherein the construct has an inner diameter from about 125 μm to about 500 μm.8. The composition of claim 1 , wherein the length of the construct is from about 0.1 mm to about 10 cm.9. The composition of claim 1 , wherein the composition comprises at least one axon extending uni- ...

PEPTIDE FOR COATING SURFACES

The invention relates to a peptide comprising (i) a main chain comprising at least one L-3,4-dihydroxyphenylalanine (DOPA), (ii) at least one integrin binding peptide, and (iii) at least one heparin binding peptide. The invention further relates to a coating for metal surfaces comprising the peptide according to the invention and a coated metal surface that can be obtained by reacting the peptide according to the invention with a metal surface. 1. A peptide comprising (i) a main chain comprising at least one L-3 ,4-dihydroxyphenylalanine (DOPA) , (ii) at least one integrin binding peptide , and (iii) at least one heparin binding peptide.2Mytilus edulis.. The peptide according to claim 1 , wherein the main chain is derived from a protein from the mussel3. The peptide according to claim 1 , wherein the peptide further comprises non-peptidic components.4. The peptide according to claim 1 , wherein the main chain comprises the sequence Cys-PEG-DOPA-Lys-DOPA-PEG-L-propargylglycine-β-Ala-NH(SEQ ID NO:2).5. The peptide according to claim 1 , wherein the at least one integrin binding peptide comprises the amino acid sequence Arg-Gly-Asp.6. The peptide according to claim 5 , wherein the at least one integrin binding peptide comprises the amino acid sequence c[Arg-Gly-Asp-D-Phe-Lys].7. The peptide according to claim 1 , wherein the at least one heparin binding peptide comprises the amino acid sequence Phe-His-Arg-Arg-Ile-Lys-Ala (SEQ ID NO:1).8. A coating for metal surfaces comprising a peptide according to .9. The coating according to claim 8 , wherein the metal surface substantially consists of titanium.10. The coating according to claim 8 , wherein the metal surface is part of an implant that is for implantation into the human or animal body.11. The coating according to claim 10 , wherein the implant is selected from the group consisting of dental implants and orthopaedic implants.12. A coated metal surface that can be obtained by reacting a peptide according to with a ...

ABSORBABLE STENT HAVING A COATING FOR CONTROLLING DEGRADATION OF THE STENT AND MAINTAINING pH NEUTRALITY

A biocompatible metallic material may be configured into any number of implantable medical devices, including intraluminal stents. The biocompatible metallic material may comprise a magnesium alloy. The magnesium alloy implantable medical device may be designed to degrade over a given period of time. In order to control the degradation time, the device may be coated or otherwise have affixed thereto one or more coatings, one of which comprises a material for controlling the degradation time and maintain a pH neutral environment proximate the device. Additionally, therapeutic agents may be incorporated into one or more of the coatings on the implantable medical device.

Oleophilic lubricated catheters

A medical device wherein the device has an outer surface coated with an oleophilic lubricous coating or the device is formed from a mixture including a polymer and an oleophilic compound.

Engineered Protein Coating for Medical Implants

Engineered protein coatings are provided for medical implants to promote bone regeneration. The coating is an engineered protein containing an elastin-like structural domain (SEQ ID No: 2) and a cell-adhesive domain derived from an extended fibronectin RGD sequence. The surface of the medical implant is covalently and directly bonded to the coating via photoreactive crosslinking through an insertion and/or addition reaction. The engineered protein coating can be applied directly upon fabrication of the implant, which would eliminate applying the coating in the operating room. The engineered protein coating is also customizable and can include biologics to improve performance. Furthermore, the engineered protein coating could also be spatially patterned on the implant surface. 1. A bone interfacing medical implant , comprising:(a) a bone interfacing coating for promoting bone regeneration, wherein the coating is an engineered protein containing an elastin-like structural domain (SEQ ID No: 2) and a cell-adhesive domain derived from an extended fibronectin RGD sequence; and(b) a medical implant with its surface covalently and directly bonded to the coating via photoreactive crosslinking through an insertion or an addition reaction.2. The bone interfacing medical implant as set forth in claim 1 , wherein the elastin-like structural domain comprises a repetitive amino acid sequence of the form (VPGXG)(SEQ ID No: 2) claim 1 , where X is an amino acid and n is at least 5.3. The bone interfacing medical implant as set forth in claim 2 , wherein at least 5% of X residues are K amino acids.4. The bone interfacing medical implant as set forth in claim 1 , wherein the extended fibronectin cell-binding sequence is TVYAVTGRGDSPASSAA (SEQ ID No: 3).5. The bone interfacing medical implant as set forth in claim 1 , wherein the cell-adhesive domain comprises at least a RGD sequence.6. The bone interfacing medical implant as set forth in claim 1 , wherein the surface is covalently ...

PARTIALLY COATED STENTS

A medical product comprises a biodegradable filament and a non-biodegradeable coating. The biodegradable filament forms a stent body having a first end portion, a middle portion, and a second end portion opposite the first end portion. The middle portion extends between the first and second end portions. The non-biodegradeable coating encapsulates the at least one biodegradable filament along the middle portion of the stent body. The non-biodegradeable coating forms a barrier such that the non-biodegradeable coating prevents degradation of the at least one biodegradable filament along the middle portion. The first and second end portions are uncoated. After implantation, the end portions of the stent may biodegrade. The middle portion will not biodegrade due to its encapsulation by the non-biodegradeable coating.

FACTOR XII INHIBITORS FOR THE ADMINISTRATION WITH MEDICAL PROCEDURES COMPRISING CONTACT WITH ARTIFICIAL SURFACES

An inhibitor of FXII/FXIIa for the prevention of the formation and/or stabilization of thrombi during and/or after a medical procedure performed on a human or animal subject comprising contacting blood of said human or animal subject with artificial surfaces, wherein said inhibitor of FXII/FXIIa is administered before and/or during and/or after said medical procedure. 120-. (canceled)21. A method of preventing or reducing a risk of thrombi formation or stabilization of formed thrombi in a human or animal subject during and/or after a medical procedure , comprising(A) administering to the subject an inhibitor of FXII/FXIIa before and/or during and/or after the medical procedure in an amount sufficient to prevent or reduce the risk of thrombi formation or stabilization during and/or after the medical procedure, and [{'sup': '2', '(i) is exposed to at least 80% of the blood volume of the subject and the artificial surface is at least 0.2 m,'}, '(ii) is a container for collection of blood outside the body of the subject, and/or', '(iii) is a stent, valve, intraluminal catheter, or a system for internal assisted pumping of blood., '(B) contacting blood of the subject with an artificial surface, wherein the artificial surface'}22. The method of claim 21 , wherein the subject does not have an increased bleeding risk after administering the inhibitor of FXII/FXIIa claim 21 , as determineda) via the ear or finger tip bleeding time method according to Duke and wherein said ear or finger tip bleeding time is not longer than 10 minutes,b) according to the method of Ivy and wherein the bleeding time is not longer than 10 minutes, and/orc) according to the method of Marx and wherein the bleeding time is not longer than 4 minutes.23. The method of claim 21 , wherein the medical procedure comprises one or more ofi) a cardiopulmonary bypass,ii) oxygenation and pumping of blood via extracorporeal membrane oxygenation,iii) assisted pumping of blood (internal or external),iv) dialysis ...

Partially coated stents

A medical product comprises a biodegradable filament and a non-biodegradeable coating. The biodegradable filament forms a stent body having a first end portion, a middle portion, and a second end portion opposite the first end portion. The middle portion extends between the first and second end portions. The non-biodegradeable coating encapsulates the at least one biodegradable filament along the middle portion of the stent body. The non-biodegradeable coating forms a barrier such that the non-biodegradeable coating prevents degradation of the at least one biodegradable filament along the middle portion. The first and second end portions are uncoated. After implantation, the end portions of the stent may biodegrade. The middle portion will not biodegrade due to its encapsulation by the non-biodegradeable coating.

BIOLOGICAL MATERIAL AND METHOD OF MANUFACTURING THE SAME

The present invention provides a biological material including a parylene C film; and first proteins which are adsorbed on the surface of the parylene C film. According to an embodiment of the present invention, the biological material further includes second proteins different from the first proteins adsorbed on the surface of the parylene C film. According to an embodiment of the present invention, the first proteins or the second proteins include BMP-2, fibronectin or PRP. 1. A biological material , comprising:a parylene-C film; andfirst proteins which are adsorbed on a surface of the parylene-C film.2. The biological material according to claim 1 , wherein the biological material further comprises second proteins different from the first proteins adsorbed on the surface of the parylene-C film.3. The biological material according to claim 1 , wherein the first proteins or the second proteins comprise BMP-2 claim 1 , fibronectin or PRP.4. A method of manufacturing a biological material claim 1 , comprising:providing a substrate;performing a vapor deposition process such that a parylene-C film is deposited on the substrate; andproviding a protein solution, wherein the parylene-C film is immersed in the protein solution to form a surface substance on the parylene-C film.5. The method of manufacturing a biological material according to claim 4 , further comprising:after forming the surface substance on the parylene-C film, performing a rinse process to rinse the surface substance.6. The method of manufacturing a biological material according to claim 4 , wherein the surface substance has biological functions.7. The method of manufacturing a biological material according to claim 6 , wherein the biological functions comprise cell proliferation and/or osteogenesis.8. The method of manufacturing a biological material according to claim 4 , wherein the protein solution comprises BMP-2 claim 4 , fibronectin and/or PRP.9. The method of manufacturing a biological material ...

Bioresorbable, endoscopic dcr stent

A stent and associated method maintains a lacrimal duct in an open, unobstructed state following DCR. The self-expanding, bioresorbable tubular structure has a diameter in the range of 5-8 mm and a length in the range of 4-8 mm following self-expansion. A mesh structure includes struts interconnected through shape-memory hinge regions that open to facilitate expansion. The structure may assume an hour-glass form having a necked-down waist region and flared opposing end regions following expansion to assist in maintaining the stent in position. The stent is compressed to a diameter in the range of 1-3 mm, loaded into an inserter tool, and positioned into a lacrimal duct having an inner wall. The stent is inserted into the lacrimal duct, whereby the stent self-expands into a structure that conformally applies outward pressure to the inner wall of the lacrimal duct to hold open the duct, and the inserter tool is removed.

DRY EYE TREATMENT DEVICES AND METHODS

Devices can be implanted in an eye to treat a dry eye condition. The devices include a body defining a lumen and having first and second ends and external and lumenal surfaces. The body has a length sufficient to provide fluid communication between the anterior chamber and tear film of the eye through the lumen when the device is implanted in the sclera. In some embodiments, the device is filterless. In some embodiments, a filter is included. The dry eye treatment devices provided herein prevent bacterial ingress, provide outflow resistance to retain a normal intraocular pressure, and provide moisture (e.g., aqueous humor) to an otherwise dry eye. Methods of treating a dry eye condition wherein the device is implanted in the sclera of an afflicted eye are also described. 119.-. (canceled)20. A device for treating a dry eye condition , the device comprising:a body having a distal end portion, a proximal end portion, and a mid-body portion extending between the distal end portion and the proximal end portion, the body defining a lumen extending along a longitudinal axis of the body between the distal end portion and the proximal end portion, the body having external and lumenal surfaces, the body having a longitudinal length sufficient to provide fluid communication between an anterior chamber and a tear film of the eye through the lumen when the device is implanted in a sclera of the eye, the mid-body portion being laterally narrower than some portions of each the distal end portion and the proximal end portion.21. The device of claim 20 , whereina proximal edge of the proximal end portion is radiused.22. The device ofwherein a maximum longitudinal length of the body in comparison to a maximum lateral width of the body is a ratio between 1:1 to 3:1.23. A method for treating a dry eye condition claim 20 , the method comprising:{'claim-ref': {'@idref': 'CLM-00020', 'claim 20'}, 'providing the device of ; and'}implanting the device in the sclera of the eye such that ...

Silicone gel-coated wound dressing

A wound dressing product that includes a substrate layer having an upper surface and a lower surface; a tacky silicone coating composition present on the upper surface and on the lower surface; and upper and lower release sheets covering the substrate and the tacky silicone coating composition on the upper and lower surfaces, respectively, and adhered to the surfaces by the tacky silicone coating composition, wherein the upper surface is less tacky than the lower surface whereby the upper release sheet can be removed from the upper surface more readily than the lower release sheet can be removed from the lower surface. Also provided are methods for making such dressings.

INTRINSICALLY DISORDERED PROTEIN BRUSHES

The disclosure relates to molecular protein brushes and devices comprising regions of protein brushes. 1. A protein brush comprising:(a) a substrate,(b) a plurality of polypeptides, each polypeptide having a first end and second end, wherein the first end is linked to the substrate, wherein the polypeptides comprise a sequence of amino acids selected so as to not form secondary structure and having a desired primary sequence of charged amino acid residues so as to modulate bristle length and/or conformation,wherein the polypeptides change conformation with the ionic and/or pH of the environment.2. The protein brush of claim 1 , wherein the polypeptide is linked to the substrate with an anchoring group selected from the group consisting of hydroxyl group claim 1 , a thiol group claim 1 , an azide group claim 1 , a carboxylic acid group claim 1 , an amide group claim 1 , an amine group claim 1 , an epoxide group claim 1 , a vinyl group claim 1 , peptide bond and a trichlorosilane group.3. The protein brush of claim 1 , wherein the polypeptide contains a large and substantially equal number of cationic and anionic amino acids.4. The protein brush of claim 1 , wherein the polypeptide comprises at least one or more phosphorylatable amino acids selected from serine claim 1 , threonine and tyrosine.5. The protein brush of claim 4 , wherein the phosphorylatable amino acids and be phosphorylated or dephosphorylated to modulate the charge on the amino acid.6. The protein brush of claim 1 , wherein the polypeptide comprises repeating sequences of charged amino acids.7. The protein brush of claim 6 , wherein the repeating units comprise tri-peptides containing lysine and proline.8. The protein brush of claim 1 , wherein the polypeptide comprises a sequence of about 30 to 100 amino acids in length that is at least 90-100% identical to SEQ ID NO:1 or SEQ ID NO:2.9. The protein brush of claim 8 , wherein the polypeptide comprises a sequence that is at least 95% identical to SEQ ID ...

Compositions and Methods for the Prevention and Treatment of Osteolysis and Osteoporosis

This application discloses compositions, devices, and methods for the prevention and treatment of osteolysis and osteoporosis. Treatment or prevention of osteolysis or osteoporosis is carried out by targeting the enzyme, Shp2 (a Src homology 2 (SH2) domain containing non-transmembrane Protein Tyrosine Phosphatase (PTP)), or proteins involved in the Shp2 signaling pathway by administering a Shp2 pathway inhibitor that inhibits fusion of pre-osteoclasts. 1. A method of treating or preventing osteolysis or osteoporosis , comprising identifying a subject comprising osteolysis or osteoporosis or comprising a risk for developing osteoporosis , and administering to said subject a Shp2 pathway inhibitor , wherein the Shp2 pathway inhibitor inhibits fusion of pre-osteoclasts.2. The method of claim 1 , wherein the Shp2 pathway inhibitor comprises a Shp2 inhibitor.3. The method of claim 2 , wherein the Shp2 inhibitor binds to the catalytic site of Shp2.4. The method of claim 2 , wherein the Shp2 inhibitor binds to an amino acid comprising the protein tyrosine phosphatase (PTP) domain of Shp2.5. The method of claim 2 , wherein the Shp2 inhibitor binds to one or more amino acids in human Shp2 claim 2 , wherein the one or more amino acids are selected from the group consisting of K280 claim 2 , Y279 claim 2 , N280 claim 2 , R362 claim 2 , H426 claim 2 , S460 claim 2 , A461 claim 2 , I463 claim 2 , G464 claim 2 , and R465 claim 2 , or an homologous residue thereof of a non-human Shp2.6. The method of claim 2 , wherein the Shp2 inhibitor inhibits an activity of human Shp2.7. The method of claim 6 , wherein the human Shp2 comprises the amino acid sequence of SEQ ID NO: 2.8. The method of claim 2 , wherein the Shp2 inhibitor prevents binding of Shp2 to a binding partner.9. The method of claim 8 , wherein the binding partner is Gab1 or Gab2.10. The method of claim 2 , wherein the Shp2 inhibitor comprises NSC87877 claim 2 , SPI-112 claim 2 , SPI-112Me claim 2 , PHPS1 claim 2 , SHP2 ...

Vascular graft for interposition at a resection of vasular structures

The invention pertains to a vascular graft ( 1 ) for interposition at a resection of vascular structures, said vascular graft comprising a hollow body ( 2 ) elongated along a longitudinal axis ( 3 ) which includes a first end ( 4 ) defining a first opening ( 5 ) and a second end ( 6 ) defining a second opening ( 7 ), wherein said resection of vascular structures concerns a resection of the carotid bifurcation, and wherein said first end ( 4 ) is configured to be attached to the common carotid artery and said second end ( 6 ) is configured to be attached to the internal carotid artery or the external carotid artery, and wherein said vascular graft comprises polytetrafluoroethylene, and wherein said vascular graft comprises an inside diameter which decreases from said first end ( 4 ) towards said second end ( 6 ).

Biodegradable Triblock Copolymers For Implantable Devices

The present invention is directed to polymeric materials made of biodegradable, bioabsorbable triblock copolymers and implantable devices (e.g., drug-delivery stents) containing such polymeric materials. The polymeric materials may also contain at least one therapeutic substance. The polymeric materials are formulated so as to improve the mechanical and adhesion properties, degradation, biocompatibility and drug permeability of such materials and, thus, implantable devices formed of such materials. 2. The implantable device of claim 1 , wherein the tensile modulus of the hard A and A′ blocks independently is greater than about 1 claim 1 ,000 MPa claim 1 , and the tensile modulus of the soft B block is less than about 1 claim 1 ,000 MPa.3. The implantable device of claim 1 , wherein the weight fraction of the A and A′ blocks is from about 1% to about 99% of the triblock copolymer.4. The implantable device of claim 1 , wherein the A claim 1 , B and A′ blocks each independently comprise a polymer comprising from one to four different types of monomer claim 1 , wherein each type of monomer has from about 5 to about 5 claim 1 ,000 monomer units.5. The implantable device of claim 1 , wherein the A and A′ blocks are the same.6. The implantable device of claim 1 , wherein the A and A′ blocks are different.7. (canceled)8. (canceled)9. The implantable device of claim 1 , wherein the B block is immiscible with the A and A′ blocks.10. The implantable device of claim 1 , further comprising at least one dihydroxyaryl group conjugated to the polymer ends of the triblock copolymer.11. The implantable device of claim 10 , wherein the at least one dihydroxyaryl group contains a 3 claim 10 ,4-dihydroxyphenyl moiety.12. The implantable device of claim 1 , further comprising at least one biocompatible moiety.13. The implantable device of claim 12 , wherein the at least one biocompatible moiety is selected from the group consisting of poly(ethylene oxide) claim 12 , poly(propylene glycol ...

THREE DIMENSIONAL TISSUE COMPOSITIONS AND METHODS OF USE

Engineered tissue compositions for supporting cell growth, maintenance, and/or differentiation featuring a scaffold, extracellular matrix (ECM) material, and optionally a population of ECM-generating cells such as fibroblasts. The tissue compositions may be used for supporting seeded cells of a particular cell type of interest such as cells related to skeletal muscle, smooth muscle, cardiac tissue, gastrointestinal tissue, etc. The tissue compositions with seeded cells may develop into functional tissues, which may have the potential to provide a tissue graft for therapeutic purposes or a valuable model for in vitro assays. 1. A tissue composition comprising:a. a scaffold with pores therein, wherein at least a portion of the scaffold is constructed from slow-degrading material, the slow-degrading material resorbs, absorbs, or degrades in a time frame no less than 1 month after culture or implantation; andb. extracellular matrix (ECM) material disposed on the scaffold or on and within the scaffold.2. The tissue composition of claim 1 , wherein the slow-degrading material comprises proteins claim 1 , polymers claim 1 , or a plurality of fibers.3. The tissue composition of claim 1 , wherein the tissue composition does not spontaneously fold onto itself during implantation.4. The tissue composition of claim 1 , wherein the scaffold has a pore size from 500 μm to 1200 μm.5. The tissue composition of claim 1 , wherein at least a portion of the scaffold is resorbable claim 1 , absorbable claim 1 , or degradable in a time frame up to 3 years following implantation into a subject.6. The tissue composition of claim 1 , wherein at least a portion of the scaffold is non-resorbable.7. The tissue composition of claim 1 , wherein the tissue composition further comprises ECM-generating cells in the ECM claim 1 , wherein the ECM-generating cells are live claim 1 , dead claim 1 , or a portion of the ECM-generating cells are dead.8. The tissue composition of claim 7 , wherein the ECM- ...

COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES

The present disclosure relates to compounds, which are useful for regulating the expression of apolipoprotein A-I (ApoA-I), and their use for treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis. 130.-. (canceled)3233.-. (canceled)34. The compound according to claim 31 , or a pharmaceutically acceptable salt thereof claim 31 , wherein for W—(R) claim 31 , W is N and Ris hydrogen; and{'sub': '7', 'Ris selected from hydroxyl and alkoxy.'}35. The compound according to claim 34 , wherein the compound of Formula II 3-(4-hydroxy-3 claim 34 ,5-dimethyl phenyl)-6 claim 34 ,8-dimethoxy-7-(morpholinomethyl)isoquinolin-1(2H)-one or a pharmaceutically salt thereof.36. The compound according to claim 34 , or a pharmaceutically acceptable salt thereof claim 34 , wherein Rand Rare each independently alkyl;{'sub': '2', 'Ris hydrogen; and'}{'sub': '7', 'Ris selected from hydroxyl and alkoxy substituted with a hydroxyl.'}37. The compound according to claim 36 , wherein the compound of Formula II is 3-(4-hydroxy-3 claim 36 ,5-dimethylphenyl)-6 claim 36 ,8-dimethoxyisoquinolin-1(2H)-one or a pharmaceutically acceptable salt thereof.39. (canceled)40. The compound according to claim 31 , wherein the compound of Formula II is selected from:3-(4-(2-(dimethylamino)ethoxy)-3,5-dimethylphenyl)-6,8-dimethoxyisoquinolin-1(2H)-one;3-(4-hydroxy-3,5-dimethylphenyl)-6,8-dimethoxy-2,7-dimethylisoquinolin-1(2H)-one;or a pharmaceutically acceptable salt thereof.41. A compound selected from:3-(4-Hydroxyphenyl)-2H-isoquinolin-1-one;4-Isoquinolin-3-yl-phenol;4-(Isoquinolin-3-yl)phenyl 2-amino-5-guanidinopentanoate tetrahydrochloride;4-(1-Oxo-1,2-dihydroisoquinolin-3-yl)phenyl 2-amino-5-guanidinopentanoate trihydrochloride;4-(6,8-dimethoxyisoquinolin-3-yl)-2,6-dimethylphenol;4-(6,8-dimethoxyisoquinolin-3-yl)-2,6-dimethylphenoxy)ethyl)morpholine;or a pharmaceutically acceptable salt thereof.42 ...

BIOFILM PREVENTION, DISRUPTION AND TREATMENT WITH BACTERIOPHAGE LYSIN

The present invention provides methods for the prevention, control, disruption and treatment of bacterial biofilms with lysin, particularly lysin having capability to kill Staphlococcal bacteria, including drug resistant , particularly the lysin PlySs2. The invention also provides compositions and methods for use in treatment or modulation of bacterial biofilm(s) and biofilm formation. 115-. (canceled)16StaphylococcusStreptococcus. A method for preventing , disrupting or eradicating a Gram-positive bacterial biofilm comprising and/or bacteria , which method comprises:{'i': Staphylococcus', 'Streptococcus, 'contacting the biofilm with a composition comprising a lysin polypeptide effective to kill and/or bacteria in a biofilm,'}wherein the lysin polypeptide comprises a CHAP domain comprising SEQ ID NO: 3 or a variant thereof having at least 80% identity to the polypeptide of SEQ ID NO: 3, and an SH3 domain, orwherein the lysin polypeptide comprises an SH3 domain comprising SEQ ID NO: 4 or a variant thereof having at least 80% identity to the polypeptide of SEQ ID NO: 4 and a CHAP domain,wherein the biofilm is on a surface, and wherein the biofilm is disrupted or eradicated or wherein establishment of the biofilm on the surface is minimized.17. The method of claim 16 , wherein the lysin polypeptide comprises the CHAP domain of SEQ ID NO: 3 or a variant thereof having at least 80% identity to the polypeptide of SEQ ID NO: 3.18. The method of claim 16 , wherein the CHAP domain comprises SEQ ID NO: 3.19. The method of claim 16 , wherein the lysin polypeptide comprises the SH3 domain of SEQ ID NO: 4 or a variant thereof having at least 80% identity to the polypeptide of SEQ ID NO: 4.20. The method of claim 16 , wherein the SH3 domain comprises SEQ ID NO: 4.21. The method of claim 16 , wherein the surface comprises a surface of a medical device.22. The method of claim 16 , wherein the medical device is a catheter claim 16 , a valve claim 16 , a prosthetic device claim 16 , ...

Surface-independent, surface-modifying, multifunctional coatings and applications thereof

The present invention provides a surface-independent surface-modifying multifunctional biocoating and methods of application thereof. The method comprises contacting at least a portion of a substrate with an alkaline solution comprising a surface-modifying agent (SMA) such as dopamine so as to modify the substrate surface to include at least one reactive moiety. In another version of the invention, a secondary reactive moiety is applied to the SMA-treated substrate to yield a surface-modified substrate having a specific functionality.

拉伸非织造物和膜

本发明提供向吸收性织物和由这些吸收性织物制成的产品提供拉伸回复的弹性聚合物组合物和其制备方法。

一种记忆合金缝合钉及缝合器

本发明公开一种记忆合金缝合钉，包括钉梁和钉脚，钉脚有两个，分别同向连接在钉梁的两端，缝合钉的记忆形状为B形或O形或C形；本发明还公开了适用于上述记忆合金缝合钉的缝合器。本发明可在腔镜下快速地完成组织或内植入物的缝合、固定操作，操作简单，对周围组织刺激小，缝合、固定的效果好。

Surface-modified metal and method for modifying metal surface

Partially coated stents

의학 제품은 생분해성 필라멘트(110) 및 비생분해성 코팅(112)을 포함한다. 생분해성 필라멘트는 제1 말단 부분(104), 중간 부분(108) 및 제1 말단 부분을 마주보는 제2 말단 부분(106)을 가지는 스텐트 바디(100)를 형성한다. 중간 부분은 제1 말단 부분과 제2 말단 부분 사이로 연장된다. 비생분해성 코팅은 스텐트 바디의 중간 부분을 따라 적어도 1종의 생분해성 모노필라멘트를 캡슐화한다. 비생분해성 코팅은 장벽을 형성하여 비생분해성 코팅은 중간 부분을 따른 적어도 1종의 생분해성 모노필라멘트의 분해를 방지한다. 제1 말단 부분 및 제2 말단 부분은 코팅되지 않는다. 이식 후, 스텐트의 말단 부분은 생분해성일 수 있다. 중간 부분은 비생분해성 코팅에 의한 이의 캡슐화로 인해 생분해성이 아닐 것이다. The medical product includes a biodegradable filament 110 and a non-biodegradable coating 112. The biodegradable filament forms a stent body 100 having a first end portion 104, a middle portion 108 and a second end portion 106 facing the first end portion. The intermediate portion extends between the first end portion and the second end portion. The non-biodegradable coating encapsulates at least one biodegradable monofilament along an intermediate portion of the stent body. The non-biodegradable coating forms a barrier such that the non-biodegradable coating prevents decomposition of at least one biodegradable monofilament along the middle portion. The first end portion and the second end portion are not coated. After implantation, the distal portion of the stent may be biodegradable. The middle portion will not be biodegradable due to its encapsulation by a non-biodegradable coating.

Manufacturing method for antibacterial titanium implant and antibacterial titanium implant by thesame

본 발명은 항균 티타늄 임플란트의 제조방법에 관한 것으로서, 은(Ag) 나노입자가 분산된 전해액을 제조하는 단계; 및 상기 은 나노입자가 분산된 전해액에 티타늄 임플란트를 양극으로 하여 플라즈마 전해산화 코팅을 수행하는 단계를 포함한다. 또한, 본 발명의 항균 티타늄 임플란트는 표면에 은(Ag) 나노입자가 0.5wt% 이상으로 분산된 다공성 코팅층이 형성된 것을 특징으로 한다. 본 발명은, 플라즈마 전해산화 코팅 공정의 전해액에 나노입자를 분산시킴으로써, 은 나노입자를 포함하는 코팅층이 표면에 형성되어 자체적으로 항균 능력이 있는 티타늄 임플란트를 제조할 수 있는 효과가 있다. 나아가, 본 발명의 항균 티타늄 임플란트는, 플라즈마 전해산화 코팅 공정을 통해서 넓은 표면적을 갖는 코팅층에 은 나노입자를 포함시킴으로써, 티타늄 임플란트의 골유착력을 향상시킬 뿐만 아니라 최소량의 은 나노입자를 통해서 항균효과를 극대화하는 효과가 있다. The present invention relates to a method for producing an antibacterial titanium implant, comprising the steps of: preparing an electrolytic solution in which silver (Ag) nanoparticles are dispersed; And performing a plasma electrolytic oxidation coating on the electrolyte solution in which the silver nanoparticles are dispersed, using the titanium implant as an anode. The antimicrobial titanium implant of the present invention is characterized in that a porous coating layer in which silver nanoparticles are dispersed in an amount of 0.5 wt% or more is formed on the surface. The present invention has the effect of dispersing nanoparticles in an electrolytic solution of a plasma electrolytic oxidation coating process, thereby forming a coating layer containing silver nanoparticles on the surface thereof, thereby producing a titanium implant having its own antibacterial ability. Further, the antimicrobial titanium implant of the present invention not only improves the bone fusion strength of the titanium implant by including the silver nanoparticles in the coating layer having a large surface area through the plasma electrolytic oxidation coating process, but also has antibacterial effect through the small amount of silver nanoparticles There is an effect of maximizing.

Manufacturing method for antibacterial titanium implant and antibacterial titanium implant by thesame

본 발명은 항균 티타늄 임플란트의 제조방법에 관한 것으로서, 은(Ag) 나노입자가 분산된 전해액을 제조하는 단계; 및 상기 은 나노입자가 분산된 전해액에 티타늄 임플란트를 양극으로 하여 플라즈마 전해산화 코팅을 수행하는 단계를 포함한다. 또한, 본 발명의 항균 티타늄 임플란트는 표면에 은(Ag) 나노입자가 0.5wt% 이상으로 분산된 다공성 코팅층이 형성된 것을 특징으로 한다. 본 발명은, 플라즈마 전해산화 코팅 공정의 전해액에 나노입자를 분산시킴으로써, 은 나노입자를 포함하는 코팅층이 표면에 형성되어 자체적으로 항균 능력이 있는 티타늄 임플란트를 제조할 수 있는 효과가 있다. 나아가, 본 발명의 항균 티타늄 임플란트는, 플라즈마 전해산화 코팅 공정을 통해서 넓은 표면적을 갖는 코팅층에 은 나노입자를 포함시킴으로써, 티타늄 임플란트의 골유착력을 향상시킬 뿐만 아니라 최소량의 은 나노입자를 통해서 항균효과를 극대화하는 효과가 있다.

Compounds for the prevention and treatment of cardiovascular diseases

본 공개내용은 아포지단백질 A-I(ApoA-I)의 발현을 조절하기에 유용한 화합물, 및 심혈관 질환 및, 예를 들면, 죽상동맥경화증과 같은 콜레스테롤- 또는 지질-관련 장애를 포함하는 관련 질환 상태를 치료하고 예방하기 위한 이의 용도에 관한 것이다. The present disclosure relates to compounds useful for modulating the expression of apolipoprotein AI (ApoA-I), and methods of treating and preventing cardiovascular diseases and related disease conditions, including cholesterol- or lipid-related disorders such as atherosclerosis And the use thereof for prevention.